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Our knowledge in biology is fundamentally based on the physical structure of the specimen, that is by 
its morphology. Different levels of morphological analyses are possible. From simple visual inspection 
down to cryo-electron microscopy or crystallography of proteins, these different levels of resolution 
are defined by the contrast generating method of choice. The most widespread approach is optical 
light microscopy, by which I refer to optical microscopy methods utilizing photons in the visible-light 
spectrum. The maximal resolution of an optical light microscope is approximately 200 nm. With 
increasing numerical aperture of the detection objective, the resolution of the system increases. 
However, while increasing resolution ~ten-fold for example, the field of view (FOV) decreases 
~hundred-fold, presenting a tradeoff between detail and scale. This phenomenon is well grasped by 
the general term “zooming in”. Due to this, imaging methods allowing for both large-scale acquisition 
and high resolution are difficult to come by. Another factor limiting the scale at which gathering 
detailed structural information by light microscopy is possible, is the limited penetration of light into 
tissue. The main reason for this is light scattering. Most of established light microscopy methods only 
allow to image a few to a maximum of few hundred micrometers of tissue thickness. Inherent to this 
problem is that it substantially prohibits investigating samples in their 3D-context. In fact, the most 
widespread and everyday application of light microscopy, which is clinical diagnostic pathology, is 
fundamentally defined by the microscopic analysis of thin tissue sections. Pathologists, and indirectly 
medical professionals in general define diseases by their 2D microscopic morphological patters. 
In the recent years, there was a renaissance of tissue clearing methods. These methods aim to turn 
biological tissue transparent. By doing so, whole-mount transparent samples can be scanned with 
special microscopes, hence un-sectioned samples become amenable to easy microscopic 3D-
reconstruction. There are still challenges in this field. For example, introducing macromolecular stains 
into large samples proves to be difficult. 
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My experimental work presented in this thesis focused on different aspect of whole-mount tissue 
imaging. First, when I started my experimental work the CLARITY method was published. The CLARITY 
method embeds and crosslinks tissue in an acrylamide-paraformaldehyde based hydrogel matrix. This 
is followed by a treatment with sodium-dodecyl-sulphate, clearing the sample of lipids. By doing so, 
light scattering between the water rich compartments and lipid-membranes in tissue decreases, thus 
leading to undisturbed light penetration. This lipid-clearing process can be done passively, meaning by 
passive diffusion of detergent molecules and lipid-laden detergent micelles. However, for making this 
process faster electrophoretic mobilization of detergent molecules and micelles was proposed. I 
strongly involved myself in mastering this method. During this process, I developed a modified version 
of this water-and ionic detergent-based clearing method. In the original electrophoretic protocol, the 
sample is placed loosely into some electrophoretic chamber, where presumably most of the ion flow 
passes through the buffer but not tissue. I proposed to isolate the sample in a way, that the two electric 
poles driving detergent-electrophoresis would be connected only through the sample. This 
constellation focuses the ion flow mostly through the sample, hence the electrophoretically mobilized 
detergents would mostly travel through the sample. Thus, washing out lipids from the sample becomes 
more efficient. Implementing these modifications through multiple iterations of hand-made and later 
3D-printed chambers, allowed for a ~10-fold increase in clearing throughput. At the same time the 
system is became also highly parallelizable. We termed this novel approach as Clearing by RapidlY 
Substituting Tissue with Acrylamide devoid of Lipids, or as CRYSTAL. 
Second, my experimental work intended to improve the introduction of molecular labels into whole-
mount optically cleared tissue. In the last years multiple approaches were proposed in parallel to my 
efforts. However, none of these became widely used until today. Since most molecular stains bare a 
net electric charge in the pH range where they are functional, I proposed to exploit electrophoresis for 
driving these dyes into tissue. Through multiple iterations of hand-crafted setups, I finally ended up in 
two 3D-printed versions which slight differed in geometric arrangement. My concept of 
electrophoretic molecular staining utilized, 1. A low-voltage system (~20 V) resulting in gentle tissue 
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treatment, 2. Focused ion flow through the sample, and 3. Scaffolding of costly reagents in a non-
crosslinking hydrogel to minimize reagent volume. These points allowed for robust molecular labeling 
of entire mouse brains within few hours. However, this approach, termed Histochemistry by 
Iontophoretic Tissue Staining or HITS, showed limitations when applied with macromolecular labels, 
such as antibodies. The reason for this was most likely the limited porosity of the tissue-hydrogel 
hybrid. Addressing this point was part of my experimental work too and will continue to be in the 
future. For addressing the problem of tissue porosity, I started experimenting with sonication which 
proved to be a promising approach and is still being pursued. My proposition was that sonication could 
potentially improve dye penetration by either modifying porosity transiently, or by inducing fluid 
streaming, or by forcing molecular labels into pressure nodes of acoustic standing waves. Additionally, 
I experimented with hydrogel variants and “intelligent hydrogels” to modify the porosity of the tissue-
hydrogel hybrid. 
Thirdly, I applied the aforementioned methodological developments to investigate the distribution of 
β-amyloid plaques (AβP) in a mouse model of cerebral amyloidosis. AβP are roughly spherical 
aggregates of the misfolded β-amyloid protein and present a major hallmark of Alzheimer’s disease 
(AD). Beyond being a pathological hallmark of this devastating and socio-economically very challenging 
neurological disease, it was shown to be involved in the pathophysiological cascade too. Hence, 
multiple therapeutic approaches aimed to prevent the brain from producing β-amyloid protein in the 
first place, or to cleanse the brain of plaques which were already generated. However, despite 
enormous efforts both in basic research and in the pharmaceutical industry, there is no viable therapy 
for AD until the very day. In most preclinical animal experiments investigating drugs targeting AβP, the 
therapeutic effect is quantified by counting the number of amyloid plaques on thin tissue sections, or 
by measuring total β-amyloid concentrations with biochemical methods. Quantifying some effect in a 
few micrometer-thin slices of tissue hardly resembles the complete response in its complexity of such 
a very heterogeneous organ, as the brain. Therefore I hypothesized, that by quantifying AβP loads in 
the entire brain, regional differences in plaque loads may emerge. Further, upon applying certain 
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drugs, the plaque-reducing effect may show regional differences in a drug-dependent manner. 
Provided this was true, this may have further implications. For example, regions with similar responses 
to a drug could be similar in some functional property. Such a result would allow one to conduct a 
similarity search (for example in gene-expression databases) between regions with similar drug-
responses. This could highlight expression patterns corresponding to certain drug-responses. This type 
of large-scale morphological analysis in our case showed, that extrapolating from observations made 
in a few sections of the brain (as done normally) may be misleading, either leading to over- or to 
underestimations of the overall drug-response. Additionally, regional differences in drug-response 
highlight a fundamental epistemological problem, namely, that if such differences emerge within an 
organ of a model system, predicting drug effects in another species based on arbitrary thin sections 
becomes even more difficult (e.g. from mouse to human). Our holistic morphological approach can be 
interpreted as a screening tool revealing 1. which brain regions will react to a treatment to what extent, 
2. which biological variables influence the effect of a treatment modality. 
Finally, as a clinical translation of the methods developed during my experimental work, we applied 
tissue clearing to human lymph nodes. Human lymph nodes bear high relevance in oncologic patient 
care, where in many cases the stage of the disease is estimated by the degree of disease spread. 
Disease spread is estimated based on local tumor extent, lymph node metastasis and metastases in 
remote organs. Hence, accurate description of tumor spread in regional lymph nodes is very relevant 
for taking therapeutic decisions and estimating disease prognosis. However, until the very day 
screening for lymph node metastases in surgical lymphadenectomies is done by classical histological 
workup. In many cases determining whether a lymph node contains cancer cells or not is concluded 
upon by looking at single few micrometers thin histological slice. We proposed, that by applying tissue 
clearing to entire human lymph nodes higher detection sensitivity may be achieved. This project is still 
ongoing; but intermediate milestones were already met. For example, we were able to scan 1mm thick 
lymph node slices. 
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In summary, my experimental work resulted in a significant improvement of the hydrogel-based tissue 
clearing approaches and in developing a simple electrophoretic staining device for whole-mount 
tissue. I applied these methods to characterize brain-wide therapeutic responses of drugs targeting 
AβPs. As a result, we saw that 1. different drugs have indeed different effect-distributions, 2. by looking 
at different descriptors of amyloid pathology at a large scale we can form pharmacodynamic 
hypotheses, 3. LIN5044 is unexpectedly potent at reducing amyloid pathology.  We further expanded 
the application of these technologies to clinical samples. During my work I learned the difficulties and 
pitfalls of developing innovative methods, in specific tissue clearing methods, and outlined further 





Unser Wissen in der Biologie beruht in fundamentaler Weise auf der physischen Struktur einer 
biologischen Probe, also ihrer Morphologie. Morphologische Analysen finden auf unterschiedlichen 
Ebenen statt. Diese unterschiedlichen Ebenen, von der simplen visuellen Betrachtung bis zur Kryo-
Elektronenmikroskopie oder Kristallographie von Proteinen, werden durch die erwünschte 
Kontrastierungs-Methode definiert. Der am weitesten verbreitete Ansatz ist die optische Licht-
Mikroskopie, die Photonen des sichtbaren Lichtspektrums verwendet. Die höchste Auflösung eines 
optischen Lichtmikroskops liegt bei etwa 200nm. Mit Zunahme der numerischen Apertur des 
verwendeten Objektivs nimmt auch die Auflösung zu. Wenn allerdings die Auflösung beispielsweise 
um das 10-Fache gesteigert wird, verringert sich das Gesichtsfeld 100-fach. Es muss daher eine 
Abwägung zwischen Detaildarstellung und Vergrößerung erfolgen. Diese zwei Seiten werden beim 
„Einzoomen“ offensichtlich. Deshalb sind bildgebende Verfahren, die gleichzeitig hohe Vergrößerung 
wie auch hohe Auflösung aufweisen, kaum realisierbar. Ein weiterer Faktor, der die strukturelle 
Darstellung mittels Lichtmikroskopie limitiert, ist die beschränkte Penetration des Lichts im Gewebe. 
Die Hauptursache dafür ist die Streuung des Lichts. Die meisten etablierten lichtmikroskopischen 
Verfahren können Gewebe nur in einer Dicke von einigen bis maximal wenigen hundert Mikrometern 
abbilden.  In der Natur der Sache liegt es dann, dass eine Probenbetrachtung in 3D zunächst 
ausgeschlossen ist. Tatsächlich beruht die häufigste und am weitesten verbreitete Anwendung der 
Lichtmikroskopie, die klinisch-pathologische Diagnostik, auf der lichtmikroskopischen Analyse dünner 
Gewebsschnitte. Damit definieren Pathologen und indirekt auch Kliniker Krankheitsveränderungen 
durch ihre morphologische Erscheinung mittels 2D-Mikroskopie. 
In den letzten Jahren fand eine Wiederentdeckung von Methoden zur Aufhellung (Clearing) von 
Geweben statt. Diese Methoden sollen biologische Gewebe transparent machen. Dann können 
transparente Gewebs- oder Organstücke im Ganzen mit speziellen Mikroskopen gescannt werden; so 
wird es ermöglicht, ungeschnittene Gewebsproben dreidimensional zu rekonstruieren. Allerdings gibt 
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es noch methodische Schwierigkeiten. Beispielsweise ist die Penetration makromolekularer Farbstoffe 
in große Gewebsproben schwierig. 
In dieser Doktorarbeit beschäftigt sich meine experimentelle Arbeit mit verschiedenen Aspekten der 
bildlichen Darstellung von Gewebsmaterial im Ganzen. In vier Ansätzen habe ich versucht, Fortschritte 
auf diesem Gebiet zu erzielen. 
Erstens beschäftigte ich mich mit der CLARITY Methode, die gerade publiziert wurde,  als ich meine 
experimentelle Arbeit begann. CLARITY bettet Gewebe in eine Acrylamid-Paraformaldehyd-basierte 
Gel-Matrix ein, die sich mit dem Gewebe vernetzt. Dann folgt eine Behandlung mit Natrium-Dodecyl-
Sulfat zur Entfernung der Lipide aus dem Gewebsstück. Dadurch nimmt die Streuung des Lichtes 
zwischen den wasserreichen Kompartements und Lipidmembranen ab, was zur Licht-Penetration ohne 
Störung führt. Der Lipid-Reinigungsprozess kann passiv erfolgen, nämlich durch passive Diffusion von 
Detergentien-Molekülen und Lipid-beladenen Detergens-Mizellen. Um diesen Prozess zu 
beschleunigen, wurde auch eine elektrophoretische Mobilisierung der Detergentien-Moleküle und –
Mizellen vorgeschlagen. Ich habe mich mit der Verfeinerung dieser Methode eingehend beschäftigt. 
In diesem Rahmen entwickelte ich eine modifizierte Version der wässrigen und ionischen 
Detergentien-basierten Methode. Im ursprünglichen Elektrophorese-Protokoll wird das Gewebe lose 
in der Elektrophorese-Kammer platziert, weshalb der Hauptteil der ionischen Durchströmung durch 
die Pufferlösung, nicht durch das Gewebe erfolgt. Ich versuchte, die Gewebsprobe so zu fixieren, dass 
die 2 elektrischen Pole der Detergentien-Elektrophorese nur über die Gewebsprobe selbst verbunden 
waren. Dieses Verfahren bündelt den Ionenstrom vor allem auf das Innere der Gewebsprobe. So 
wandern die elektrophoretisch moblilisierten Detergentien innerhalb des Untersuchungsmaterials. 
Dadurch wird das Auswaschen der Lipide effektiver. Die Anwendung dieser Modifikationen führte bei 
multiplen Versuchsanordnungen von selbstgebauten und später im 3D-Druck hergestellten 
Reaktionskammern zu einer etwa 10-fachen Steigerung der Clearing-Rate. Gleichzeitig wurde das 
System standardisiert und vergleichbar. Wir nannten diese neue Modifikation “Clearing by RapidlY 
Substituting Tissue with Acrylamide devoid of Lipids” oder CRYSTAL. 
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Zweitens bestrebte meine experimentelle Arbeit, die Verwendbarkeit molekularer Markierungen für 
optisch aufgehellte Gewebsstücke im Ganzen zu verbessern. Gleichzeitig mit meinen Bemühungen 
wurden dazu in den letzten Jahren vielfache Ansätze versucht. Allerdings hat sich bis heute keiner 
davon durchgesetzt. Da die meisten molekularen Färbungen eine elektrische Ladung im pH-Bereich 
ihrer Funktionalität aufweisen, war es meine Idee, die Elektrophorese zum Eindringen der Farbstoffe 
ins Gewebe zu verwenden. Nach zahlreichen Ausführungen selbstgebauter Geräte konnte ich 
schließlich zwei 3D-gedruckte Versionen entwickeln, die geringe Unterschiede in der geometrischen 
Ausführung aufwiesen. Mein Konzept der elektrophoretischen Molekularfärbung verwendet 1) eine 
niedrige Systemspannung (~20 V), die eine schonende Gewebsbehandlung bewirkt; 2) einen 
fokusierten Ionen-Durchfluss durch das Gewebsstück; und 3) den Einbau teurer Reagenzien in ein 
nicht-vernetzendes (non-crosslinking) wässriges Gel zur Minimierung des Reagenzienverbrauchs. 
Diese Faktoren ermöglichten die verlässliche molekulare Markierung ganzer Maushirne in wenigen 
Stunden. Allerdings zeigte diese Methode, benannt “Histochemistry by Iontophoretic Tissue Staining“ 
oder HITS, Einschränkungen bei der Verwendung von makromolekularen Markern, etwa Antikörpern. 
Der Grund dafür ist höchstwahrscheinlich die eingeschränkte Durchlässigkeit der Gewebs-Hydrogel-
Mischung. Das Angehen dieses Problems war ebenfalls Teil meiner experimentellen Arbeit und wird 
es auch in der Zukunft sein. Um das Problem der Gewebsdurchlässigkeit zu lösen, begann ich, mit 
Ultraschall zu experimentieren, was sich als vielversprechender Ansatz herausstellte und auch jetzt 
noch weiter verfolgt wird. Meine Vorstellung war, dass die Penetrationsfähigkeit der Farbstoffe durch 
Ultraschall verbessert werden kann, und zwar entweder durch vorübergehende Modifikation der 
Durchlässigkeit, durch Förderung der Durchströmung, oder durch Hineindrängen der molekularen 
Marker in Druckknoten stehender akustischer Wellen. Zusätzlich experimentierte ich mit Varianten 
des Hydrogels einschließlich eines „intelligenten“ Hydrogels, um die Durchlässigkeit der Gewebs-
Hydrogel-Mischung zu verbessern. 
Drittens wandte ich die bisher erwähnten methodischen Entwicklungen auf die Untersuchung der 
Verteilung von β-Amyloid-Plaques (AβP) in einem Mausmodell einer cerebralen Amyloidose an. AβP 
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sind annähernd kugelige Aggregate des fehlgefalteten β-Amyloid-Peptids und stellen ein 
Hauptcharakteristikum der Alzheimer-Krankheit (AD) dar. Darüber hinaus ist β-Amyloid auch in die 
pathophysiologische Kaskade dieser verheerenden und sozio-ökonomisch sehr herausfordernden 
neurologischen Krankheit eingebunden. Daher zielen viele therapeutische Ansätze darauf ab, das 
Gehirn zu allererst von der Produktion des β-Amyloid-Peptids abzuhalten, oder es von bereits 
gebildeten Plaques zu säubern. Trotz enormer Anstrengungen sowohl in der Grundlagenforschung als 
auch in der pharmazeutischen Industrie gibt es allerdings bis zum heutigen Tag keine wirkliche 
Therapie der AD. In den meisten präklinischen Tierexperimentalstudien mit Medikamenten, die gegen 
AβP gerichtet sind, wird der therapeutische Effekt durch Zählung von Amyloidplaques auf dünnen 
Gewebsschnitten quantifiziert, oder durch Messung der gesamten β-Amyloid-Konzentration mittels 
biochemischer Methoden. Die Quantifizierung der Veränderungen in wenige Mikrometer dünnen 
Gewebsschnitten ist kaum repräsentativ für die komplette Erfassung der Komplexität eines äußerst 
vielfältigen Organs wie des Gehirns. Daher war es meine Hypothese, dass durch die Quantifizierung 
der AβP-Beladung des gesamten Gehirns regionale Unterschiede hervortreten könnten. Weiters 
könnte bei Anwendung bestimmter Medikamente ein Plaque-reduzierender Effekt regionale 
Unterschiede nach Dosisabhängigkeit zeigen. Falls dies stimmen sollte, hätte es erhebliche 
Konsequenzen. Beispielsweise könnten Regionen mit ähnlichen Effekten eines Medikaments anderen 
in funktionellen Eigenschaften ähneln. Ein derartiges Resultat würde es erlauben, eine 
Ähnlichkeitsstudie (z. B. in Gen-Expressions-Datenbanken) zwischen Regionen mit ähnlichen 
Medikamenten-Effekten zu unternehmen. Das könnte Expressionsmuster in Bezug auf bestimmte 
Medikamenten-Effekte herausstellen. Dieser Typ einer morphologischen Analyse in großem Maßstab 
zeigte in unserem Fall, dass eine Extrapolation von Beobachtungen an Hand einiger weniger Schnitte 
des Gehirns (wie es normalerweise gemacht wird) irreführend sein und zur Unter- bis Überschätzung 
eines generellen Medikamenten-Effekts führen kann. Zusätzlich betonen regionale Unterschiede in der 
Medikamenten-Antwort ein fundamentales epistemologisches Problem, dass nämlich bei Auftreten 
derartiger Unterschiede innerhalb eines Organs oder Modellsystems die Übertragbarkeit der 
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Medikamenten-Effekte von einer zu einer anderen Spezies auf Basis ausgewählter Dünnschnitte noch 
schwieriger wird (z. B. von Maus zu Mensch). Unser holistischer morphologischer Forschungsansatz 
kann als Screening-Werkzeug dienen, um herauszufinden, 1) welche Hirnregion in welchem Ausmaß 
auf Behandlung ansprechen wird, und 2) welche biologische Variablen den Effekt einer 
Therapiemaßnahme beeinflussen. 
Zuletzt verwendeten wir das Gewebs-Clearing bei menschlichen Lymphknoten, um eine klinische 
Translation der Methoden meiner experimentellen Arbeit aufzuzeigen. Menschliche Lymphknoten 
sind in der Behandlung onkologischer Patienten sehr wichtig, da in vielen Fällen das Krankheitsstadium 
durch das Ausmaß der Tumorausbreitung abgeschätzt werden soll. Die Tumorausbreitung wird durch 
das lokale Tumorwachstum, Lymphknoten-Metastasen und Metastasen in entfernten Organen 
bestimmt. Die genaue Erfassung der Tumorausbreitung auf regionale Lymphknoten ist daher sehr 
wesentlich für therapeutische Entscheidungen und Abschätzung der Krankheitsprognose. Allerdings 
wird bis zum heutigen Tag das Screening auf Lymphknotenmetastasen in operativ gewonnenen 
Lymphknotenproben mittels klassischer histologischer Aufarbeitung vorgenommen. In vielen Fällen 
wird das Vorhandensein von Krebszellen in Lymphknoten durch Betrachtung eines oder mehrerer 
wenige Mikrometer dünner Schnitte bestimmt. Wir schlugen vor, dass durch die Anwendung des 
Gewebe-Clearing auf ganze Lymphknoten eine höhere Sensitivität zur Erfassung erreicht werden 
könnte. Dieses Projekt ist noch im Laufen, und Zwischenziele wurden bereits erreicht. Beispielsweise 
konnten wir Lymphknoten-Schnitte in einer Dicke von 1mm scannen, also einen viel dickeren 
Gewebsbereich erfassen, als es durch die klassische Histologie möglich ist. 
Zusammenfassend konnte durch meine experimentelle Arbeit eine bedeutende Verbesserung der 
Gewebs-Clearing-Methoden auf Hydrogel-Basis und die Entwicklung eines einfachen 
elektrophoretischen Färbesystems für Gewebe im Ganzen erzielt werden. Ich konnte die 
Verwendbarkeit dieser Methoden zur experimentellen Charakterisierung des therapeutischen Effekts 
von Medikamenten gegen AβPs im gesamten Maushirn aufzeigen. Die Resultate zeigten, dass 1) 
unterschiedliche Medikamente tatsächlich unterschiedliche Verteilungen ihres Effektes im 
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Gesamtorgan haben; 2) die Betrachtung verschiedener Merkmale einer Amyloid-Pathologie im 
ganzheitlichen Maßstab die Formulierung pharmakodynamischer Hypothesen erlaubt; und 3) LIN5044 
unerwartet effektiv in der Reduktion einer Amyloid-Pathologie ist. Zuletzt weitete ich die Anwendung 
dieser Technologien auf klinische Gewebsproben menschlicher Lymphknoten aus. Während dieser 
Studien konnte ich Schwierigkeiten und Fehlerquellen in der Entwicklung innovativer Methoden 
identifizieren, im Speziellen bei Gewebs-Clearing-Methoden. Auch konnte ich weitere Entwicklungen 
in der technologischen Innovation aufzeigen, die zum Fortschritt in verschiedenen Forschungsgebieten 









AβP- β-amyloid plaque(s) 
AD – Alzheimer’s Disease 
APS – ammonium persulfate 
BACE1 – Beta - secretase 1 
CRYSTAL - Clearing by RapidlY Substituting Tissue with Acrylamide devoid of Lipids 
FOV – field of view 
gSAV – Globally significantly affected voxels  
HITS – Histochemistry by Iontophoretic Tissue Staining 
HM – hydrogel monomer (solution) 
LCP – luminescent conjugated polythiophene 
LMA – low-melting agarose 
NFT – neurofibrillary tangles (phosphorylated tau aggregates) 
PAGE – polyacrylamide gel electrophoresis 
PBS – phosphate buffered saline 
PFA – Paraformaldehyde 
pVar – p-value variability 
SAV – Significantly affected voxels 
SAVm – Significantly affected voxel mismatch 
SDS – Sodium – dodecyl – sulphate 
SPIM – selective plane illumination microscopy 
RI – refractive index 
TEMED - N,N,N',N'-tetramethylethylenediamine 
TTB – Tris-Tricine buffer 
USW – Ultrasonic standing waves 
wSAV – weighed significantly affected voxels 
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The brief history of histology 
 
The study of the microscopic anatomy of tissue, generally known as histology (greek: ἱστός, histos for 
tissue, and λογία, logia for study), dates back to the 18th century or even earlier[1]. As early as 1716, 
Leeuwenhoek stained thin slices of skeletal muscle with alcoholic saffron solution.  Ever since, despite 
extensive developments in microscopic techniques, the slicing and staining of tissue has remained 
almost an integral component of histological examination. George Adams developed the first 
microtome to create thin tissue slices in 1770. Since then the basic technique of accessing tissue 
remains largely unchanged and the microtome has become a standard tool in all bio-medical research 
and clinical laboratories around the globe.  Clearly, the fundamental necessity of tissue slicing had a 
defining role in the development in histology. Addressing this, Spalteholz developed laborious clearing 






Figure 1. A drawing from Leeuwenhoeks work showing the microscopic structure of a one-year-old 
ash wood.  
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Since the cellular and subcellular details of native tissue are barely visible, an extensive battery of 
histochemical and immunohistochemical stains have been developed over the years[1]. Advances in 
staining techniques have developed hand-in-hand with scientific postulations regarding what materials 
and anatomical structures exist within tissues. For example, bone was initially stained with common 
madder (Rubia tinctorum) by Louis Duhamel in 1741.  Later, Krause highlighted tissue borders with 
silver nitrate in 1844 and introduced the term “epithelia”. Subsequently Julius Vogel detected iron in 
the form of sulfides in 1845. In the mid-nineteenth century, stains like carmine were introduced for 
highlighting cell nuclei and iodine for glycogen. During this fertile era, W. Waldeyer stained nerve cell 
processes with hematoxylin in 1863. As more and more stains were developed, scientific language and 
concepts were refined accordingly. Simple observations, such as the propensity of certain structures 
to bind a given dye allowed the distinction between chromophobic and chromaffinic structures, as 
described in the adrenal gland by Fr. G. J. Henle this in 1865. In 1905, Bethe expanded the investigation 
of tissue by introducing stains for functional properties such as the pH of tissue, by applying pH 
sensitive dyes. Camillo Golgi and Santiago Ramón Y Cajal were awarded the Nobel Prize for their 
histological investigations of the nervous system. As noted before, as knowledge about the matter and 
structures accrued, stains were developed to visualize these partitions, or vice versa. It is worth 
mentioning, that many of these historic staining methods continue to be used to date. A significant 
leap in tissue staining was when specific antibodies were invented to specifically visualize the 
multitude of proteins in biological tissues[4]. Antibodies are produced until today and contribute 
significantly to the ever-growing biotechnological industry. One could say, that labeling biological 
structures with antibodies or equivalent reagents is such a standard tool in the biomedical sciences 
and medicine, as using nouns to name our surroundings. Somewhat later, in situ hybridization was 





Optical clarification of biological tissue 
 
In most cases biological tissue is optically not transparent, hence the need for generating thin sections 
for microscopy. From the perspective of microscopic investigation of tissue, there are different physical 
contributors to this phenomenon. In the case of classical light microscopy, for one, the contrast is 
generated by light-absorbing dyes, where the light source is transilluminating the sample. Multiple 
layers of light-absorbing dyes lead finally to extinguished excitatory light. This is one of the reasons 
why fluorescent microscopy, where the signal is sparse and the labels are not extensively absorbing, 
had such a major impact. However, even when only sparse structures are labeled and the tissue is 
otherwise transparent (which is not the case unless processed accordingly), the superposition of 
multiple imaging planes leads finally to loss of image detail – as it happens to be the case in 
epifluorescent microscopy (Fig. 2A). With the introduction of fluorescent laser microscopy methods, 
the excitation of selected imaging planes became possible and the acquisition of structures from out-
of-focus imaging planes could be significantly reduced. This way the problem of light absorbing 
contrast generation (colorful dyes versus fluorescent dyes), and extensive superposition of information 
was overcome[6]. However, with the rise of confocal microscopy tissue could be imaged at high 
resolutions at multiple micron thin imaging planes, but this was not possible beyond a certain depth. 
Even with two-photon microscopy, the deepest images are recorded from not more than a few 
hundred micrometers down from the surface[7, 8]. Beyond that, the images become more and more 
blurred (Fig. 2B). The reason for the limited imaging depth is the heterogeneous light scattering across 
different tissue compartments, generally referred to as light scattering of tissue[9]. Strictly, light 
scattering, that is molecules absorbing unidirectional photons and emitting photons diffusely, occurs 
in every medium where light traverses. However, in case of a homogeneous medium the molecules 
excited at a given point in time cancel out their emitted waves by destructive interference (Fig. 3A-B). 
Only waves emitted along the path of the light source do not cancel out, as the subsequent molecules 
emit their waves not in phase (Fig. 3C-D). Biological tissue however, is far from homogeneous and 
essentially represents a continuous series of interfaces with alternative scattering properties or 
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refractive indexes (RI)[10] – resulting in a superposition of asynchronous scattering which is prohibitive 
to microscopy.  
 
 
Figure 2. A, Superposition of multiple imaging planes interferes with resolving structures. Having 
few structures in a thin section allows the discrimination between structures (left), while when 
more information is included in thicker section, the projected image becomes uninterpretable 
(right). B, Light scattering in tissue prohibits laser scanning microscopy in the deep, unless light 
scattering is reduced. Sharp images (left), blurry images deeper (middle), reduced light scattering 






The most relevant inhomogeneity in animal tissues in respect of light scattering, are at the interfaces 
of lipids and water. Practically, these are cellular membranes and aqueous compartments like the 
cytosol and interstitial fluids. Additional factors reducing the optical transparency of tissue are 
chromogenic light-absorbing structures, like various biological (hemosiderin, melanin) or 
environmental pigments (anthracosis). Further, large-scale protein fibers in repetitive parallel bundles 
like those in collagen fibers, can be a source of light scattering too. 
Reducing light scattering in tissue in order to render it amenable to deep imaging is generally referred 
to as tissue clearing or tissue clarification. Tissue clearing approaches went through a renaissance in 
the past years and multiple variations were published to the same end. Tissue clearing methods aim 
Figure 3. Light scattering in homogeneous media is permissive to straight light propagation and to 
microscopy. A and B (wave view), identical molecules at equal distances excited at the same time 
scatter light but destructive interference cancels out “lateral” wavelets. C and D (wave view), 
Subsequent molecules are excited at different timepoints so that their wavelets sum in the forward 
direction, causing no attenuation. (From Richardson D.S. and Lichtman J.W., 2015)  
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to homogenize RI across tissue. Since the strongest contributors to light scattering of tissue are lipid-
water interfaces, clearing approaches try to either remove lipids followed by RI homogenization, or 
solely to increase the RI of the aqueous compartment[9, 11]. As reviewed by Richardson and Lichtman, 
tissue clearing approaches can be grouped according to their working mechanism (Fig. 4). A feasible 
way to assess these different technologies are variables like final sample transparency, ease of use, 
incubation time, compatibility with fluorescent proteins and stainings, and alteration of tissue 
morphology. I refrain from providing an extensive review of these aspect across all the available 
methods, for reference see Table 1 (Appendix). Having contributed to the field and based on 
discussions with colleagues, the most discussed methods are organic solvent based techniques 
(BABB[12], 3DISCO[13], iDISCO[14, 15], uDISCO[16], vDISCO[17]) and methods utilizing hydrogel 
embedding (CLARITY[18], PARS, PACT[19], SWITCH[20], MAP[21]). The major differences between the 
two groups of methods are for one, that solvent-based techniques quench the fluorescence of 
genetically encoded fluorescent reporters. In order to reveal these, whole organs need to be stained 
with antibodies, or perfused with nanobody-based fluorescent boosters targeting the reporter 
proteins[17]. In case of hydrogel-based methods this is not necessary. Further, solvent based methods 
are easy to implement and are relatively fast, while hydrogel-based techniques are slow, unless 
facilitated with electrophoresis. However, electrophoretic facilitation makes the method more 
complicated to implement, and can result in tissue damage if not done carefully. The tissue 
hyperhydration based CUBIC[22] method raised high hopes, however in recent meetings these 
techniques were less discussed. Personal communications suggested, that RI across CUBIC treated 
tissue is not always homogeneous and is difficult to predict. Hyperhydrating methods retain the 
fluorescence of reporter proteins and are compatible with immunostains, however they tend to take 
more time to achieve transparency. Simple immersion based techniques like FRUIT[23], ClearT[24] or 
SeeDB[25], intend to increase the RI of the aqueous compartment and achieve a compromise “average 







CLARITY, belonging to the group of techniques working with hydrogel embedding and detergent-based 
lipid extraction followed by RI homogenization, is one of the most seminal methods in the field (Fig.5). 
CLARITY utilizes a fixative solution containing acrylamide and bis-acrylamide with a heat-inducible 
initiator and paraformaldehyde (PFA), to which in general I will refer as hydrogel monomer solution or 
HM. Animal models can be perfused with HM transcardially, where this is not possible samples can  
simply be passively soaked with the mixture. Following a degassing step, the HM is polymerized by 
warming up the HM to 37°C. This way the sample is embedded in a hydrogel polymer scaffold. This 
Figure 4. Tissue clearing methods can be grouped according to their working mechanism. (From 
Richardson D.S. and Lichtman J.W., 2015)  
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hydrogel support structure allows later for sodium-dodecyl-sulphate (SDS)-mediated lipid removal 
from the sample, without jeopardizing the sample’s structure. Further, with the help of PFA, proteins 
are crosslinked to the hydrogel scaffold hence proteins remain in their original location. SDS mediated 
lipid extraction can proceed passively[18], passively by continuous transcardial perfusion[19] or 
actively[18, 26, 27] by electrophoretic enhancement of molecular diffusion. Following tissue-lipid 
extraction samples are washed free of SDS and immersed into a solution homogenizing the RI. Taking 
the clearing of a mouse brain as a benchmark, lipid extraction with passive CLARITY takes several 
weeks. Active CLARITY is faster, however takes still a week or more until sufficient transparency is 
achieved. It was recently shown that by applying a novel crosslinking approach with epoxid based 
crosslinkers, harsher conditions can be used for clearing with SDS[28]. In parallel to my experimental 
work commercial active CLARITY systems were brought on the market (X-CLARITY – Logos biosystems, 





Staining of biological tissue 
 
Biological tissue contains a vast number of different molecules, mostly proteins and nucleic acids. 
These molecules are distributed in a large variety of patterns and relative localizations, which is 
considered as the portion of biological information contained in tissue. Accessing this information 
experimentally, was for a long time far from trivial (see chapter Historical aspects of histology). 
However, with the rise of antibodies and similar reagents this became possible. Over the years applying 
specific stains to various proteins became basic routine in every bio-medical or clinical pathology 
laboratory. Essentially, there is no feasibility to any microscopic method, which is not compatible with 
antibody-staining. There is an industry to provide clinics and research with instrumentation and 
Figure 5. The sequence of the CLARITY method. Sample blocks or organs are infused with hydrogel 
monomer solution. Polymerisation is initiated by heating up the solution which results in the cross- 
linking of hydrogel monomers to other monomers or polymers, proteins to proteins and proteins 
hydrogel monomers or polymers. Hydrogel embedded tissues undergo lipid extraction with SDS 
passively or by applying electrophoresis. (From Chung et al 2013, Nature) 
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reagents for antibody staining on classical histological slices. With the rise of tissue clearing methods 
the classical slice-based staining approaches utilizing passive diffusion become somewhat challenging. 
Irrespective of the tissue clearing procedure, the resulting samples are two to four orders of magnitude 
thicker than standard histological slices. Not surprisingly, this increase in sample size presents a new 
challenge for molecular phenotypisation of tissue. 
Fick’s first law states, 
𝐽𝐽 = −D dφ
dx
 
where “J” is the diffusion flux, “D” is the diffusion constant or diffusivity, “φ” is the concentration 
gradient and “x” is the distance between the measurement points. In other words, the rate of diffusion 
in one-dimension is proportional to the diffusion constant and the concentration gradient, while it is 
inversely proportional to distance. 
For D is true that,  
𝐷𝐷𝑇𝑇1𝐷𝐷𝑇𝑇2 = 𝑇𝑇1𝑇𝑇2𝜇𝜇𝑇𝑇2𝜇𝜇𝑇𝑇1 
where “T” refers to temperature and ”μ” is the dynamic viscosity of the solvent. This implies that 
diffusivity is proportional to temperature, but inversely proportional to the solution’s dynamic 
viscosity. In biological tissue, the picture is complicated by the relation of pores outlined by biological 
structures and the size of the solute particles. In histological staining, the most accessible and 
adjustable variables influencing dye penetration into tissue, include the concentration gradient and 
temperature. Further, tissue may be permeabilized with detergents[29] or the pore size may be 
increased[19], alternatively, the size of molecular labels decreased[30]. When comparing whole-
mount specimens to the standard histological slices, the difference in size of tissue to penetrate ranges 
from few micrometers to centimeters. At the same time, if the dye molecules are relatively large 
compared to the tissue pore size, the tissue behaves to some extent as a series of semipermeable 
membranes. The concentration of a dye in the buffer around the tissue may be high, still this results 
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only in a slow increase in the number of molecules within the tissue. Accordingly, the rate of dye 
molecules reaching points deep inside the tissue becomes dramatically slower. Hence, according to 
Fick’s law in part, the handles for attempting to tune dye diffusion in tissue include dye concentration, 
temperature, solvent viscosity, pore size and the size of the dye molecule. The amount of dye 
concentration that can be applied is limited by the high cost of dyes and by overstaining of background 
structures. The temperature of the solvent may be increased; however, most dyes are unstable at 
temperatures significantly higher than 37 °C. Modulating viscosity is limited by the fact that staining 
procedures, especially proteinaceous dyes, are water based. In a brief pilot study, I searched the 
literature for several low-viscosity organic solvents, which could potentially decrease the viscosity of 
water. Based on in vitro studies describing that acetonitrile and tetrahydrofuran admixed with water 
increase the affinity of certain antibodies[31], I proceeded with a brief pilot experiment (not shown). 
These experiments did not result in any detectable staining.  In addition, the fluorescence of 
fluorescent reporter proteins was abolished. Clearly, this approach is limited by the fact that the 
combination of these organic solvents with water osmotically dehydrates hydrated tissue, especially 
after hydrogel-embedding. This resulted in the shrinkage of the samples, which at the same time most 
likely meant that the pore sizes were decreased, thus potentially abolishing any putative beneficial 
effect of decreased viscosity and higher diffusivity. Increasing the pore size is another feasible way to 
improve dye penetration. The pore size of the sample can be manipulated by changing the composition 
of the hydrogel-fixative mixture and thereby modulate the number of crosslinks, and hydrogel 
density[19]. Another approach is osmotic hyperhydration of the sample, for example by expanding the 
hydrogel after enzymatic digestion[32], or after chaotropic agent mediated protein denaturation at 
high temperatures[21]. Modulating the hydrogel-fixative mixture also affects the volume and pore-
size change upon different osmotic conditions[19, 21]. Finally, the smaller the molecular labels, the 
faster they diffuse and the less their diffusion is influenced by spatial constraints of tissue structure, 
i.e. pore size[30]. Decreasing the size of dye molecules is an alternative method, and probably the most 
efficient one to improve diffusion through tissue. However, engineering specific and stable 
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macromolecular dye molecules is not trivial for most users. Even in experienced labs where protein 
engineering is part of the daily routine, the development of a single functioning molecule requires 
significant investment of time and resources without a guarantee for success. It is important to 
emphasize, that all possibilities discussed in this section are handles addressing passive diffusion. 
Electrophoresis is a concept deeply embedded in the repertoire of scientific methods. Since the initial 
description in 1930 by the Nobel laureate Arne Tiselius[33], devices for electrophoresis, i.e. 
electrophoretic chambers or tanks, are more or less as common in bio-medical laboratories as chairs. 
These devices, which are widely used to separate proteins (Western blot) and nucleic acids (Southern 
and Northern blot)[34-36], are routinely operated by personnel ranging from interns to experienced 
academics. The basic goal of protein gel-electrophoresis is the separation of proteins in a thin layer of 
hydrogel according to the analytes size and net charge. This separation happens parallel to the field 
vectors of a constant electric field[37]. Negatively charged proteins are repelled from the cathode and 
are forced towards the anode. Depending on their size, proteins face greater or lesser “resistance” 
when migrating through the retention medium, or hydrogel. When comparing different analytes, 
molecular mobility is mainly determined by the net charge and the effective molecular radius of the 
molecule, what is referred to as mass-to-charge ratio. However, the effective migration through a 
medium is determined by the molecular mobility combined with the strength of the electric field vector 
- counteracted by the structure of the retention medium. In the case of a hybrid tissue-hydrogel, the 
physical boundaries of the pores contribute to the retention. This so-called electrophoretic mobility 
carries multiple mathematical definitions. The most well-known definition originates from 
Smoluchowski[38].  
Electrophoretic facilitation of molecular diffusion for staining tissue when passive diffusion is limiting, 
suggested itself to me. This prompted me to develop an electrophoretic whole-mount staining method 
early on. Worth mentioning, the application of electrophoresis to drive dye molecules in order to stain 
very thin samples or peripheral nerve tracts was reported as a proof of concept almost a decade 
ago[39, 40]. In parallel to my efforts, new approaches were published working with electrophoresis[27, 
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30]. Kim and colleagues showed whole-mount labeling of entire mouse brains. However, the method 
they described was not implemented in upcoming literature citing their work (~20 papers), except two 
publications from the same laboratory. A commercial machine (Smartlabel, LifeCanvas Technologies) 
implementing their approach is promised to be marketed, however this is pending since rather a long 
time (~1-2 years). Hence, the practicality/applicability of this approach is not clear yet. Also, based on 
the corresponding publication, stochastic electrotransport requires non-feasible amounts of reagents 
(an entire vial of commercial antibody for one brain). These points altogether point to an unmet need 
for efficient whole-mount tissue staining with macromolecules. 
 
Sonication for the facilitation of molecular mobility 
 
Ultrasound has a wide variety of applications ranging from everyday medical diagnostics, sensors, 
cleaners and bio-medical research. Improving drug penetration through skin and sclera by applying 
kilohertz range sonication was shown in multiple works. Some authors explain this phenomenon by a 
transient shift in tissue porosity [41-44]. In another example, enhanced formalin fixation was shown 
by using megahertz – range ultrasound [45]. In most of these cases, ultrasound is applied in a 
continuous wave setting. In a few works however, ultrasonic standing waves (USW) were utilized to 
enhance e.g. the sensitivity of serologic assays [46-48]. The principle of these works is based on the 
phenomenon of the acoustic radiation force dragging molecules into the pressure nodes of USW fields 
[49-51] (Fig. 6). With decreasing particle size (e.g. 200 nm), the particles behaviour tends to be 
governed by ultrasonic microstreaming - behaviour, also called as Rayleigh streaming, which is less 
likely in case of particles above or in the micrometre range[51]. The former, where particles are 
accumulating in pressure nodes, increases the probability of binding partners to interact. The latter at 
the same time, where particles circulate rapidly within a small radius in the pressure node, is proposed 
to increase the frequency of interactions between binding partners. One may think about the latter as 







Imaging of tissue 
 
The optical microscopy techniques available to the scientific community are vast. Starting from simple 
bright-field microscopes to non-linear microscopy techniques like single molecule localization super-
resolution microscopy. With tissue clearing methods becoming popular, the demand for a technology 
bridging large FOV, three-dimensional resolving power, imaging speed and micron-range lateral 
resolution was formulated. Confocal microscopy being very popular in biomedical sciences, can reach 
lateral resolutions of ~200 nm. However, scanning sample volumes in the range of millimeters to 
centimeters is slow and is not feasible. Light sheet microscopy or selective plane illumination 
microscopy (SPIM) provides a compromise. Here a thin sheet of light is shone through a transparent 
Figure 6. Temporal sequence of suspended particle aggregation in USW. Homogeneously 
distributed particles (a). Particles move towards and concentrate in the nodal plane (b), followed 
by aggregation (c). Formula describing the acoustic radiation force where P0 is wave amplitude, V 
is particle size, λ is wavelength and (β, ρ) describes particle compressibility. (Modified from 
Spengler et al 2003, AIChe Journal) 
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sample (Fig.7)[12, 52, 53]. The portion of the sample which is illuminated in a sheet-like fashion, is 
referred to as optical section. Fluorophores in the excited plane emit photons, which are collected onto 
a CCD camera with an orthogonal detection objective. By sampling the tissue with optical sections, it 
can be reconstructed into a volume digitally. This results in the acquisition of an entire FOV instantly. 
This way overview images (e.g. 10 µm/voxel isotropic) from entire mouse brains can be generated in 
5-10 minutes. A challenge with SPIM is for one the anisotropy between the lateral and the axial 
resolution. The former is defined by the detection optics, the latter by the light sheet thickness and 
optical slicing steps. It is not trivial to go beyond 3 µm axial resolution, while the lateral resolution is 
theoretically limited by Abbe’s limit (~200 - 250 nm)[54]. Second, it is challenging to maintain a 
homogeneous light sheet thickness throughout the FOV. However, the field of SPIM being a 
dynamically developing one, several innovative tricks were introduced to overcome some of the 
artefacts. For example, with electrically tunable lenses the light sheet thickness can be tuned to be 
homogeneous throughout the FOV [55]. 
 
  
Figure 7. The principle of selective plane illumination microscopy. The translucent sample is trans-
illuminated with a sheet of light. The photons emitted from the sample are collected orthogonally. 






Animal care and experimental protocols were all performed in compliance with the Swiss Animal 
Protection Law and with the Swiss Ethical Principles and Guidelines for Experiments on Animals, under 
the approval of the Veterinary office of the Canton Zurich. All efforts were made to minimize animal 
discomfort and suffering. 
Experiments were performed on APP/PS1 [56] and Thy1-YFP [57] mice. 
 
Drug treatments 
APP/PS1 mice were either treated with NB-360[58] BACE1-inhibitor (Novartis) via food-chow (0.5 g 
inhibitor/kg chow, ~6 g chow/day/mouse = 3mg inhibitor/day/mouse), or with the β1 monoclonal IgG1 
antibody recognizing amino acids 3 to 6 of human Aβ [59, 60] (Novartis) (0.5 mg/week, once/week in 
200µl intraperitoneally), or with LIN5044[61] 100µl 1x week intraperitoneally (4 mg/ml). Control mice 
were treated with control chow, non-specific IgG and PBS respectively. Ages on average for the old NB-
360, antibody and LIN5044 treated group were 353 days (21 days STD), 313 days (9 days STD) and 308 
days (7 days STD) respectively. Ages on average for the young NB-360, antibody and LIN5044 treated 
group were 61 days (3 days STD), 59 days (2 days STD) and 65 days (2 days STD) respectively. 
 
Tissue-Hydrogel Hybridization 
3-month-old Thy1-YFP, 5– or 13-month old APP/PS1 mice were deeply anaesthetized (defined as 
abolished reflexes and seized breathing) by injecting intraperitoneally a 250 µl mixture of Rompun 
0.5% (Bayer AG) and Ketalar 25 mg\ml (Parke-Davis) and processed as previously published (Chung et 
al. 2013). Briefly, mice were perfused with 20 ml ice cold phosphate-buffered saline (PBS) followed by 
20 ml ice cold hydrogel monomer containing 4% (v/v) acrylamide (Biorad Cat.# 161-0144), 0.05% (v/v) 
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bisacrylamide (Biorad Cat.# 161-0142), 4% or 1% (v/v) paraformaldehyde (Sigma-Aldrich P6145), 0.25% 
(v/w) VA-044 initiator (Wako Pure Chemical Industries, Ltd). In some experiments, the mixture 
contained 4% (v/v) instead of 1% (v/v) paraformaldehyde. After careful brain extraction samples were 
kept in 20 ml of hydrogel monomer solution at 4 °C overnight. After this samples were degassed in a 
desiccator chamber for 15 minutes and purged with nitrogen until pressure equilibrated. Samples were 
polymerized at 37 °C for 2.5 hours with constant slow rocking. Brains were gently extracted from 
polymerized gels with soft tissue paper and washed with clearing buffer overnight. Clearing buffer is a 
200 mM boric acid-buffered (Sigma Aldrich, #15663) 8% (w/v) SDS (Sigma Aldrich Cat.# 74255) [19]) 
solution. 
 
Tissue clearing for Alzheimer’s disease treatment study 
Hydrogel-hybridized whole-mount mouse brains were stored in clearing buffer at room temperature 
until processed. Brains were mounted in the sample mounting plunger-tubes of the custom-made 3D-
printed CRYSTAL chambers. Sample mounting plungers were inserted in the respective chamber and 
fixed with two clamps. After opening the valves on the tubing, the pumping of clearing buffer was 
started. The chambers were briefly tilted to force trapped air bubbles out. The CRYSTAL setup and 
buffer reservoirs were stored in an incubator to hold temperatures of 39.5 °C. Electrophoresis was set 
to 130mA current-clamped mode with 60V upper voltage limit. Clearing was visually assessed and 
around half-way clearing the polarity of the power supply was switched. Clearing time varied between 
2.5-8 hours, however within sub-cohorts (littermates perfused together) clearing times were 
reproducible. 
 
Whole-brain staining for Alzheimer’s disease treatment study 
Whole brain stains with HITS were prepared as described in the chapter describing the development 
of HITS (see “Whole-mount mouse brain staining with HITS”).  Briefly, samples were rigorously washed 
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clean of clearing buffer with tris-tricine electrophoresis buffer (TTB) (50 mM tris, 50 mM tricine, pH 
8.5) (four times in 30 ml TTB). HITS chambers with acrylamide electric plugs were prepared previously. 
Briefly, 9 ml of 10 % acrylamide/bis-acrylamide (BioRad #161-0140) in TTB cross-linked with 10% 
ammonium persulfate (APS) and tetramethylethylendiamine (TEMED) was pipetted in each chamber 
(the effective ratio of ammonium persulfate (BioRad #1610700) and N’,N’,N’,N’-
tetramethylethylendiamine (BioRad # 161-0801) were for 20 ml of total mixture volume 8 µl TEMED 
and 200 µl 10 % APS).. The chamber not designed to contain the dye later, was casted in a way so that 
a filter paper is at the electric-plug surface. Low-melting agarose (LMA) (Invitrogen #16520-100) was 
dissolved in TTB to reach 1% w/v by boiling the mixture in a microwave briefly. 600 µl of LMA was 
pipetted in a 1 ml tube and put in a 37°C water bath. For staining amyloid plaques a combination of 
LCPs was used[62]. qFTAA and hFTAA were dissolved in water at 10 mM concentrations. Ten µl of each 
dye was pipetted into the liquid LMA at 37°C. The LMA-LCP mixture was then pipetted into the 
acrylamide plug designed to hold the dye, which was rapidly followed by placing the sample into the 
mixture – which gelled within a minute at room temperature. After this a spacer piece was mounted 
around the sample. Two ~ 2 ml of mineral oil (Sigma Aldrich #M3516) were pipetted around the sample 
into the spacer. Next, the opposing chamber was mounted so that its acrylamide plug was facing the 
sample, and all three pieces (chamber with the sample – spacer - chamber) were joined together by 
screwing in two bolts across them. The chambers were filled with 20 ml of TTB each, and the lids with 
platinum electrodes were attached. Dye – electrophoresis was run for 2 hours at 20 V constant voltage 
mode. Chambers were then disassembled. As samples tended to stick to the filter paper, they were 
gently removed and placed into 20 ml of TTB for one hour which was followed by washing in phosphate 
buffered saline for two hours (PBS). This was followed by refractive index matching. 
 
Refractive index matching 
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Refractive index matching solution (RIMS), RI 1.46, was prepared as previously published [19]. Briefly, 
100 g of Histodenz (Sigma Aldrich, Cat.# D2158), 75 ml of PBS, 0.1 % v/v Tween-20 (Sigma Aldrich, Cat.# 
P2287) and 0.01 % w/v Sodium-Azide were mixed. As a new component I added 42 ml of 
triethanolamine (Sigma Aldrich, Cat.# 90278). The benefit of adding triethanolamine was to increase 
the volume of the solution by 30% while keeping the refractive index constant, a cost saving measure, 
since RIMS solution is expensive (2 $/ml instead of 3 $/ml). Another benefit of adding triethanolamine 
was that it effects further clarification of inhomogeneities in the sample [22]. After brains were 
thoroughly washed with PBS, they placed into 2 ml of RIMS overnight with slow rocking. Afterwards, 2 
ml of RIMS was discarded and replaced by 4 ml of fresh RIMS. After another 12 hours of incubation the 
brains were ready for imaging. 
 
Imaging 
Brain slices were imaged with a Leica SP5 confocal microscope. Whole brain images were recorded 
with a custom made selective plane illumination microscope (SPIM) or a confocal microsope (Leica 
SP8). For SPIM imaging. after clearing and refractive index matching, transparent brains were attached 
to a small weight and loaded into a 10x20x45 mm quartz cuvette (UQ-205, Portmann Instruments), 
then submerged in RIMS and imaged using a home-built mesoscale single-plane illumination 
microscope (mesoSPIM). The sample cuvette was immersed in a 40x40x40 mm quartz cuvette (UQ-
753, Portmann Instruments) filled with index-matching oil (19569, Code 50350, Cargille, nD=1.45) 
which allows XYZ & rotation movements of the sample without refocusing the detection path. The 
instrument consists of a dual-sided excitation path using a fiber-coupled multiline laser combiner (405, 
488, 515, 561, 594, 647 nm, Omicron SOLE-6) and a detection path comprising an Olympus MVX-10 
zoom macroscope with a 1x objective (Olympus MVPLAPO 1x), a filter wheel (Ludl 96A350), and a 
scientific CMOS (sCMOS) camera (Hamamatsu Orca Flash 4.0 V3). The excitation paths also contain 
galvo scanners (GCM-2280-1500, Citizen Chiba) for light-sheet generation and reduction of streaking 
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artifacts due to absorption of the light-sheet. In addition, the beam waist is scanned using electrically 
tunable lenses (ETL, Optotune EL-16-40-5D-TC-L) synchronized with the rolling shutter of the sCMOS 
camera. This axially scanned light-sheet mode (ASLM) leads to an uniform axial resolution across the 
field-of-view (FOV) of 4-10 µm (depending on zoom & wavelength). Image acquisition is done using 
custom software written in Python ( https://github.com/mesoSPIM/mesoSPIM-control ) Field of views 
ranged from 10.79 mm at 1.25x magnification (Pixel size: 5.27 µm) for overview datasets, 3.27 mm at 
4x (Pixel size: 1.6 µm) to 2.62 mm at 5x (Pixel size: 1.28 µm). The laser/filter combinations were as 
follows: For  hFTAA at 488 nm excitation a 498 – 520 nm bandpass filter (BrightLine HC, AHF) was used 
as emission filter; for qFTAA at 488 nm excitation a 565 - 605 nm bandpass filter (Chroma, AHF). Further 
technical details of the custom SPIM will be described elsewhere (http://www.mesospim.org). For 
more details see mesoSPIM.org. 
 
Computational pipeline 
The following was performed using custom scripts written in Python and R, as well as existing third-
party libraries (see below). The 2-channel (498 and 565 nm) substacks for each brain hemisphere were 
first stitched together. The result was then down-sampled from the acquired resolution (3.26 um 
lateral, 3 um depth) to an isotropic 25 um resolution and was then registered to the Allen Institute 25 
um average anatomical template atlas. This was performed automatically using a combination of affine 
and b-spline transformation registrations, with parameters influenced from previous studies 
performing mouse whole-brain fluorescence quantification studies[15].  The resulting pair of 
transformations are used in subsequent steps to transform coordinates in the raw data space to the 
template atlas space. 
The 565 - 605 nm channel at its original resolution was used to determine the locations of aggregates 
of amyloid-β stained with qFTAA and hFTAA. Background fluorescence from this volumetric data was 
first removed by subtraction of the morphological opening of the original image, with a structure 
element size that was experimentally determined to be 5 pixels in each spatial dimension.  The local 
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maxima of the resulting image are obtained, and all of these points are used as the starting points for 
a watershed segmentation, with a threshold background intensity parameter that was experimentally 
determined. The radius of each aggregate is then calculated from this binarized watershed image. 
Points are filtered using a combination of their intensity value and radius in order to exclude aggregates 
that are too small to accurately consider. These locations were used to look up the peak intensity of 
each plaque in the 498 nm channel, and plaque maturity was calculated as the plaque’s peak intensity 
in the 498 nm channel divided by its peak intensity in the 565 nm channel.  
After downsampling each aggregate point to the 25um resolution and applying the optimized 
registration transformation, the number of aggregates were counted at each voxel in this atlas space, 
with the resulting volume being called a “heatmap.” Voxel-level statistics across treated and control 
brains first involved low pass filtering each heatmap and running a two-sided t-test at each voxel across 
the two groups. The transformed locations of each plaque were also further grouped into the 700 
different anatomically segmented regions in the Allen Atlas for further statistical analysis between 
longitudinal groups. Similar heatmap generation, voxel statistics, and regional statistics were 
performed for three other metrics: the total plaque volume in each 25um voxel, the mean plaque 
volume in each 25um voxel, and the mean plaque maturity in each 25um voxel. 
  
Key Resources Table (see also References[63-66]) 
 
Software and Algorithms Source 
OpenCV Bradski, G. (2000). The OpenCV Library. Dr. Dobb's Journal 
of Software Tools. 
 
Elastix S. Klein, M. Staring, K. Murphy, M.A. Viergever, J.P.W. 
Pluim, "elastix: a toolbox for intensity based medical 
image registration," IEEE Transactions on Medical Imaging, 




ClearMap Renier, N., Adams, E. L., Kirst, C., Wu, Z., Azevedo, R., Kohl, 
J., . . . Tessier-Lavigne, M. (2016). Mapping of Brain Activity 
by Automated Volume Analysis of Immediate Early Genes. 
Cell, 165(7), 1789-1802. doi:10.1016/j.cell.2016.05.007 
Python Python Software Foundation. Python Language Reference, 
version 2.7. Available at http://www.python.org 
 
SciPy K. Jarrod Millman and Michael Aivazis. Python for 
Scientists and Engineers, Computing in Science & 
Engineering, 13, 9-12 (2011), DOI:10.1109/MCSE.2011.36 
 
R R Core Team (2013). R: A language and environment for 
statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. http://www.R-project.org  
 
WholeBrain Fürth, D., Vaissière, T., Tzortzi, O., Xuan, Y., Märtin, A., 
Lazaridis, I., . . . Meletis, K. (2017). An interactive 
framework for whole-brain maps at cellular 




Native polyacrylamide gel electrophoresis (PAGE) 
Samples were dissolved in a ratio of sample, running buffer, sample buffer and water; 1 : 5 : 2.5 : 1 
respectively. 2-3 µg of protein sample was loaded per lane. Commercial 3-12 % Bis-Tris polyacrylamide 
gels were used (NativePAGE, Novex, ThermoFisher #BN1001BOX). Gels were run at 20 V constant 
voltage, at various pH and buffer conditions (see results). Gels were stained with the SilverXpress silver 
staining kit (ThermoFisher #LC6100). 
 
Immunohistochemistry 
For the buffer tests, antibodies against the N-terminus of the amyloid precursor protein (β1-antibody, 
kindly provided by Paolo Paganetti, IRB Bellinzona, CH) and NeuN conjugated to Alexa 555 (Millipore, 
MAB377A5) were used. For buffer compositions and staining conditions, see the corresponding section 





Development of Clarification by Rapidly Substituting Tissue with Acrylamide devoid of Lipids 
 
My experimental work started by working on establishing the CLARITY method[18]. Facing some 
challenges while working on CLARITY prompted me to assess the method, understand its working 
principle and tackle some modifications. This expanded into a project on its own which I will elaborate 
on. In this part of my thesis I will summarize the steps for establishing the CRYSTAL method starting 
from early hand-fabricated prototypes to user-friendly computer designed devices.  A detailed 
description of this work can be found in my MD-thesis from 2017. 
 
The CRYSTAL hypothesis 
 
The guiding principle while establishing CRYSTAL was to critically assess the electrophoretic CLARITY 
approach and to improve the protocol. I hypothesized that the efficiency of CLARITY could be improved 
by focusing the electric current through the tissue. My argument was that electric resistance of lipid-
laden tissue is significantly higher than that of the surrounding ionic buffer solution. In an 
electrophoretic process, the ions carrying the charges will follow the path of least resistance. Hence, 
in case of CLARITY, SDS molecules will preferentially travel in the buffer surrounding the tissue rather 
than through the tissue (Fig. 8C). This unfocused electric flow could result in a superfluous electrolytic 
consumption of clearing buffer as well as heat generation, and non-efficient lipid extraction from the 
sample. This in the end would lead to prolonged incubation times, and potentially to tissue damage 






For the original electrophoretic CLARITY protocol (Fig. 8A), the electrophoretic chamber was 
constructed from plastic laboratory dishes (Nalgene) where two parallel platinum electrodes were 
glued into a plastic container. The chamber also incorporated a buffer inflow and outflow port (Fig. 
8B). The opeinings accomodating the fluid connectors or electrodes were melted into the vial with a 
soldering iron and the individual items were glued in with a two component epoxy glue. As described 
in the CLARITY protocol I included a membrane filter in the system. Later this item was exluded, since 
the advantage of using it was not clear. 
The CLARITY setup was tested on few occasions only. During the runs several problems occurred. It 
was very difficult to avoid leakage within the system, which required regular intervention. Thus, 
continuous and undisturbed runs were difficult to maintain. Additionally, the brain samples turned 
brown or were displaced and sticked to the electrode. After these few unsuccesful attempts, I had to 




My first proof-of-concept approach used the same tools as in the CLARITY system, but they were 
modified so that the electric current would be focused through the tissue. For this I fabricated a 
prototype in which the tissue served as the only medium connecting the two buffer reservoirs 
electrically (Fig. 8C-E). I achieved this by drilling a hole in a wide flat-bottom tube approximately the 
size of a brain. Then I sealed the opening from the outside with tape and positioned the brain above 
the opening inside the tube. Following this step, I poured liquid paraffin into the tube covering the 
entire bottom surface and reaching ~3 mm in depth. After the paraffin hardened, liquid low melting 
agarose was cast into the tube just as much as to cover the sample. The tube was then closed with the 
original lid, which was modified to contain an electrode (cathode). I put the assembled tube into the 
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outer buffer container, which also accommodated the anode. The buffer in the tube in contact with 
the sample, was circulated during the runs. 
 
Figure 8. The CLARITY setup and the first CRYSTAL test. The original chamber schematic from Chung 
et al 2013, Nature (A). A CLARITY chamber built according to the original protocol (B). Conceptual 
difference between CLARITY and CRYSTAL. While current flows rather through the highly 
conductive buffer in CLARITY, current with SDS micelles flow more through the tissue in CRYSTAL 
(C). Schematic of the first CRYSTAL prototype, which is based on an inner and outer container (grey 
tube and black outer box respectively). The bottom of the inner container accommodates a 2 cm 
diameter opening, connecting the buffer reservoir in the outer and inner container. The tissue 
(purple) is embedded above this opening in layers of paraffin and agarose (yellow filling in the tube) 
providing a seal around the tissue. The cathode (black spiral) is placed in the inner container, the 
anode (red spiral) in the outer container and both containers are filled with clearing solution (SDS). 
Current flow from the inner tube through the tissue towards the outer tube is shown by the blue 
arrow (D). A photograph of the inner reservoir containing a sample surrounded by paraffin wax and 






After some iterations of hand-fabricated prototypes, I designed contraption which allowed for an open 
liquid-circulation system and simplified handling. By this I mean, that both buffer fractions had contact 
to atmospheric pressure, and that I avoided the laborious steps of sealing the sample with paraffin wax 
and agarose. I achieved this by creating two open buffer tanks which were connected by a tube, where 
the two buffer tanks and the tube were independent pieces, but nevertheless water – tight when 
assembled. The tube connecting the tanks provided the electric bridge and contained the sample (Fig. 
9). In order to seal the sample in the tube, we developed a mold to cast silicone polymer (Sylgard 184, 
Dow Corning) plugs replacing the paraffin – agarose composite (Figure 9). Two plugs were inserted into 
the plexiglass tube, after which the tube was clamped between the two buffer tanks.  The silicone plug 
included a void in its center to contain the sample (Figure 9C), further each plug contained an electrode 
ending in the central void.  The buffer inflow also trespassed through the silicone and directly flushed 
the electrode. From the central void, the clearing buffer exited into the buffer tank. The sample was 
kept from directly contacting the electrode by putting a small net between the electrode and the 
sample. This arrangement achieved with the silicone plugs proved to be a robust solution. A silicone 
plug could be reused several times. Only, after a while the soldering of the electrode cable and the 
platinum wire - which was surrounded by silicone tightly -, wore off. This was due to the local 
electrolytic process of the soldering iron, since minute amounts of clearing buffer leaked back along 
the electrode. Another advantage of the silicone plugs was their transparency, which allowed us to 
assess the condition of the sample during the run. To get an exact impression of the clearing process 
however, the sample still had to be taken out of the contraption. By including multiple holes on the 
buffer tanks multiple tubes could be clamped in-between them. Superfluous holes were sealed by 






In order to make the clearing process successful, it turned out that tight temperature control of the 
system was necessary. One extreme, namely too much heat lead to sample browning and burning. This 
I learned from my first experiments with the original CLARITY setup, and from personal communication 
with other scientists in the field. The other extreme, cold temperatures lead on the one hand to the 
precipitation of SDS (below 15°C). On the other hand, below certain temperatures the viscosity of lipids 
is increasing making their extraction and clearing difficult. Therefore, I had to construct a thermostat 
which allowed for in-flow temperature control, both heating and cooling. By in-flow I mean, that the 
temperature needed to be assessed and controlled directly in the tubing entering and exiting the 
clearing chamber. This thermostat needed to be flexible in the sense that I could change the control-
algorithm and set values depending on the experimental requirements. To this end I used an Arduino 
microcomputer which I could program via USB. In order to convey the weak signals from the Arduino 
towards the effective switching of a powerful in-flow heater-cooler unit, I had to include an amplifier. 
Figure 9. The third CRYSTAL prototype. The main parts of 
the device were two buffer tanks with multiple openings. 
These openings were either connected by tubes or blocked 
by Teflon plugs (white) (A-B). Two silicone plugs were 
pushed into the tube from the opposite sides, facing each 
other. Each silicone plug contained a sample-holding void, 
where the buffer inflow of the pump directly flushed the 
sample and the electrode (C). The buffer exited the plug 




Taken together I created a thermostat, where I have built temperature sensors into the tubing, which 
informed an Arduino, where my algorithm processed this signal and switched an amplifier (Fig. 10, and 
appendix). The amplifier was a simple Boolean logical device based on three-transistor, switching two 
relays (Fig. 11 and Fig. 12). One relay served simply as an on/off switch, while the second relay was a 
bipolar-bistable relay, allowing for switching the polarity of the power mains going to the heat-transfer 
unit. I built a heat-transfer unit which consisted a processor cooler, conveying the heating or cooling 
of a Peltier-element attached to it (Fig. 13). The polarity and the switching frequency of the Peltier-
element determined the temperature of the buffer. The data collected from the sensors by the Arduino 
was saved on an SD-memory card. This data could be plotted after each run, by which some limited 
assessment of each CRYSTAL-run could be made. For example, if there was some interruption of the 
liquid-circulation, that was visible by a swift change in temperature (Fig. 14). 
 
Figure 10. Schematic depiction of the concept of the thermostat. The direction of information flow 
is represented by arrows. The blue arrows represent information collected by the in- flow and out-
flow sensors (in-flow s. and out-flow s.) from the buffer, the red arrows represent control signals 
towards the buffer via the amplifier and the heater/cooler. The whole process is controlled by a 




Figure 11. The wiring diagram of the amplifier. The main components are the relays and the logical 
circuit switching the relays. Each relay-coil is controlled by a transistor, which are controlled by the 
Arduino. The logical diodes only allow circuit flow in one direction; thus, it is possible to switch the 






Figure 13. Photograph of the heat exchanger of the thermostat. The clearing buffer was flowing 
through the processor cooler. The heat adsorbing side of the processor cooler was attached to a 
Peltier - element with heat paste. The Peltier - element functioning as a heat pump could either 
heat or cool the processor cooler while respectively cooling or heating the radiator or the other 
side. The radiator was subject to continuous air flow with the help of the attached fan. 
Figure 12. The thermostat control unit. 
Schematic depiction of information flow 
in the thermostat (A), where based on 
the sensor reads the user-defined set 
temperature and switching delay (the 
period the Peltier - element is on), the 
algorithm generates an output. The 
Arduino board used in the setup (B), with 
the amplifier below (C, amplifier in red 
bracket). On the amplifier board the 
small white box is the master relay, 
behind it the larger brown box is the 
polarity switch relay. The LCD screen of 
the thermostat showing in-flow, out- 
flow and the set temperature (D). A 
small SD – card break out board to save 
the recordings (E). Digital temperature 
sensors glued into syringe caps (F) and 
inserted into a T – junction inserted into 





As mentioned before, after burning some samples I tried to cool the system which resulted in failure 
to clear the samples. At lower temperatures decreasing lipid fluidity and micelle formation hinders 
lipid removal [67]. This prompted us to test the highest possible operating temperature, where the 
system remained to be stable. By the stability of the system I mean for example that while still working 
with the agarose – paraffin sealing, high temperatures softened the paraffin and the sandwich tended 
to fall apart. Finally, after some runs we figured an optimal temperature of 39.5 °C, which we have 
used ever since successfully. 
Figure 14. An exemplary recording saved on the SD – card. At a set temperature of 42 °C (grey line) 
the inflow buffer temperature (blue dots) flowing directly from the CRYSTAL chamber into the 
heater lies around 42 °C - indicating good temperature control. The outflow temperature exiting 
the heater towards the CRYSTAL chamber (orange – colored dots) is naturally higher than the in – 
flow, in order to account for the cooling effect of the environment. The steep rise at the beginning 
of the plot shows the system heating up from room temperature. Sharp dips in the recordings 
usually occurred when, e.g., there was a leak in the tubing, thus giving indirect feedback about the 
stability of the system. 
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Our final clearing protocol for whole-mount mouse brains is defined by a temperature of 39.5°C , 130 
mA constant current mode with a voltage limit of 60 V. With these settings the clearing of a mouse 
brain embedded in 4% acrylamide; 0.05% bis-acrylamide and 1% PFA hydrogel took 2-8 hours. 
Variability in clearing time was depending on many factors, like the quality of transcardial perfusion or 
the age of the mouse, which were mostly non-controllable. 
At this stage we decided to create a scalable and user-friendly CRYSTAL-clearing prototype. For this we 
designed (with the help of Michael B. Smith, Novartis, Cambridge MA, US) a miniature chamber 
containing all the previously discussed features but tailored to fit a mouse brain (Fig. 15). These devices 
were designed digitally and were 3D-printed. 
 
 
Some examples of fluorescent images recorded from CRYSTAL-cleared samples are shown in Figure 
16. 
 
Figure 15. 3D-printed CRYSTAL chambers. Cross-section of a chamber showing individual 
components with different color (A) and a complete chamber (grey insert). Clearing solution is 
circulated independently at the two ends of the chamber around one electrode each. The tissue is 
contained in a sample-holder plunger (green), while the tissue is separated from the electrodes by 
small nets (blue). The plunger is sealed by a rubber ring (black). Samples are positioned within the 




Figure 16. Results after CRYSTAL clearing. A highly transparent cleared Thy1 – YFP mouse brain 
after refractive index matching (A). Rendering of the cortical surface from a Thy1-YFP brain 
recorded with SPIM (B), a two-photon microscopy stack from a similar sample from the cortical 
surface deep down (>1500 µm) reaching the hippocampus (C). An optical cross-section from an 
APP/PS1 mouse brain with amyloid plaques stained with LCP (D). Confocal microscopy data from a 
cleared APP/PS1 brain where the vessels were stained with CM-DiI (red), the amyloid plaques with 
LCP (green) (E). Rendering of confocal stacks from wildtype (F) and APP/PS1 (G) samples with 




Development of Histochemistry by Iontophoretic Tissue Staining 
 
In this section I will discuss the building blocks of the HITS system, including the device itself as well as 
crucial reagents such as buffers, and how these were optimized. This will be followed by a step by step 
description of setting up a HITS run. Finally, a simple way of validation of the HITS method will be 
illustrated. 
 
The HITS chamber 
All gel-electrophoretic systems contain a chamber integrating a buffer system, a retention medium 
(gel), the sample migrating in the gel and electrodes with a power supply attached (Fig. 17[68]). 
Samples are loaded into and contained in preformed wells, separating various samples in the same gel. 
In our HITS setting, the retention medium is the hydrogel embedded tissue itself. The electrophoretic 




Figure 17. A schematic illustration of a classical agarose gel electrophoresis chamber used for the 
separation of nucleic acids. The main components of the system are the gel as a retention medium, 
the negative and positive electrodes (cathode and anode, respectively) connected to a power 
supply and the electrophoresis buffer providing ions for conductivity and for stabilizing the pH. 
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The principle goal of the HITS device is to apply electrophoresis in order to maximize diffusion of dye 
molecules through tissue. This technique, analogous to the classical electrophoresis setting (Fig. 17), 
requires electrodes, containment for the running buffer, and means of confining the target molecules. 
The primary difference of HITS from classical electrophoresis is the retention medium. While in 
classical electrophoresis the gels are highly standardized and strictly defined both chemically and 
geometrically, these standards do not apply to the HITS method (Fig. 18). In HITS, the retention 
medium is our hydrogel embedded sample, with considerable sample variability. The sample variability 
originates from the biological variability between animals, from differences between different organ, 
and from technical factors in tissue processing steps prior to HITS. This results in a wide range of 
chemical-structural and morphological variability across samples. Morphological variability is an aspect 
that can be potentially addressed when designing a HITS device. Hence, in an optimal setting, the 
device should allow flexibility across a range of sample morphologies. Another difference between 
HITS and classical gel-electrophoresis is that in contrast to the classical setting where the analyte is 
added to the system in liquid form, in HITS the dye is embedded in a non-cross-linking hydrogel. This 
allows to minimize the volume of reagents used for staining, since there is no need to dilute dyes in 





The early versions of HITS were partially handmade (Fig. 9, 19), while the current models are computer 
designed and 3-D printed (Fig. 20, 21). In the first system, two buffer reservoirs were connected with 
a tube containing the sample, using the same setup as for CRYSTAL (Fig. 9). Within this tube, the sample 
had to be positioned and stabilized.  Moreover, here it was especially important to have the sample 
being the only conducting medium between the two electric poles. In order to address this issue, I 
developed a protocol for constructing a sandwich around the sample, consisting of multiple layers of 
electrically conductive agarose-gel and electrically isolating paraffin (Figure 19). Briefly, first a 3-4 mm 
layer of paraffin was cast into the tube, which had been previously sealed with tape. The center of the 
paraffin layer contained a well measuring 10 mm in diameter. On this layer, a 3-4 mm layer of 2% low-
melting-agarose at 37 °C was cast. Before this layer completely solidified, the sample was positioned 
above or close to the well in the paraffin layer. This agarose layer filled the well in the paraffin and 
represented one of the electric contact surfaces of the sandwich towards the buffer. Next, a small 
plastic tube was positioned around the sample and the large tube was again filled with paraffin. This 
layer sealed the agarose layer from the top surface, while not covering the sample due to the small 
Figure 18. Schematic 
representation of the HITS 
-concept. Negatively 
charged dye particles 
(green dots) migrate from 
the cathode to the anode 
in an electric field. Along 
this course, molecules are 
forced to cross the tissue 
sample. Electrophoresis is 




tube protecting it. As a next step, 1 % low-melting- agarose was cast into the small tube over the 
sample, filling the spaces around the sample and providing a flat surface for applying the dye in the 
next step. The dye was dissolved in 1 ml of 1 % low-melting-agarose and was poured into the tube. 
Note that the two electrically conductive surfaces of the sandwich are the agarose filling the paraffin-
constrained well, and the solidified dye-agarose mixture. In other words, any electric current 
exchanging between the two electrodes has to flow through these structures and cross the tissue in 
between. When the last layer solidified, the sandwich was ready to be mounted into the chamber. 
After this step, the buffer reservoirs were filled with buffer, the electrodes were mounted into the 
buffer adjacent to the two openings of the plexiglass tube and the HITS-run was ready to be started.  
 
 
The sandwich consisted 1 % and 2 % low-melting-agarose. The reason for this was that while the 
tougher 2% agarose at the bottom layer served as an electrically conductive mechanical support, the 
1% agarose layers merely guided the current and contained dye. The lower density agarose is beneficial 





In the latest version of HITS-design, we aimed to avoid the multiple steps of sandwich casting and 
reduced the amount of buffer used in a run. At the same time, we maintained the flexibility of 
accepting various tissue morphologies while limiting electric conductance to the tissue only. We 
devised a device using computer aided design with the help of Michael B. Smith (Novartis, Cambridge 
Figure 19. The HITS sandwich in the early HITS devices. In the center, the schematic design of the 
sandwich is depicted. The layers were cast from bottom to top starting with a paraffin layer with a 
central well. This well was then filled with 2% agarose, where the brains were positioned, while the 
gel still not completely solid. (I).  Plastic tubes were then positioned around the brains and the 
whole surface covered with liquid paraffin (II). After an intermediate layer of 1% agarose was 
poured into the small tubes above the brains (not shown), the dye dissolved in 1% agarose was 




MA, US) (Figure 20), which then was 3D printed (Figure 21). We set up this device by casting an 
acrylamide plug into the outlet of each chamber in order to seal the buffer and establish contact to 
the tissue. After this, one side of the chamber was positioned so that the agarose surface was 
horizontal. At this point the low-melting-agarose mixed with the dye was applied on the acrylamide 
surface. After the low-melting-agarose - dye mixture was applied, the tissue was mounted. 
Subsequently, an insert of appropriate thickness was placed around the tissue so that only a 1-2 mm 
of tissue emerged above the level of the insert. This 1-2 mm of extra tissue above the level of the 
inserts, served as the contact surface to touch the acrylamide plug of the opposing chamber. The 
acrylamide of the opposing chamber, which was mostly the anodic side, was covered with a buffer-
soaked filter paper in order to avoid the anionic tissue from sticking to the acrylamide. Following this 
step, the other side of the chamber could be placed on the insert, and the three plastic parts – chamber 








Figure 20. Computer aided design of the HITS chamber as a whole (grey insert) and in cross-section. 
First, each block was covered at the side for the electric contact surface with a lid (not shown), 
after which 10% acrylamide was poured into the chamber and was allowed to polymerize. The dye 
in 1% low-melting-agarose was cast on the acrylamide plug and the sample was placed on it. The 
sample was then secured with the insert piece, after which the other side of the chamber was 
attached and fixed with bolts. The buffer reservoirs were filled with buffer and the lids containing 






In protein electrophoresis, the goal is to physically separate proteins, that is to focus them into sharp 
bands according to their electrophoretic mobility. To achieve this goal isotachophoresis is used, which 
is based on utilizing a particular buffer composition[69]. Buffers for isotachophoresis contain a salt 
system to stabilize the pH and a zwitterionic component. The fundamental idea is to devise a buffer 
system with three migrating ions: a fast, a medium and a slow ionic component. Protein analytes 
comprise the component with medium electrophoretic mobility, which are squeezed into a band by 
the faster leading and slower terminating ions. In the classical setting, proteins are coated with sodium-
dodecyl-sulfate (SDS) and are unequivocally negatively charged. The leading ion is a small anion such 
as chloride. The terminating ion must be a molecule with an isoelectric point around the pH of the 
buffer in order to harbor only limited charge and reduced electrophoretic mobility. Some amino acids 
fulfill this criterion and are broadly used for this purpose. In my view, isotachophoresis is another 
promising method for driving dye molecules. By retaining a relatively sharp migration band, I assumed 
Figure 21. 3D prints of the computer 
designed HITS chamber disassembled 
(top) and assembled (bottom). The 
right chamber (right block on the top) 
includes filter paper on the 
acrylamide. This is always included on 
the side of the cathode in order to 




that the dye molecules will achieve high local concentrations, hence saturate dye-binding sites. By 
keeping the dyes relatively confined to bands, one possibly also assures that the dyes leave the sample 
around the same time and do not drag a diffuse lagging “tail”. However, these are hypothetical 
considerations and difficult to test in tissue. 
There are two principles when selecting the optimal conditions for electrophoresis buffers for HITS. 
First, the conditions should provide a reasonable electrophoretic migration speed. Second, the 
conditions should be compatible with the binder-epitope binding. These two criteria work in opposing 
directions to some extent. By increasing the charge of the dyes, e.g. proteins, the system is driven 
towards greater electrophoretic mobility but at the same time pushing this to the extreme can 
denature proteins and abolish their binding. In SDS-PAGE for example, which is one of the most widely 
used electrophoretic settings, the proteins are coated with negative charges. However, SDS also 
denatures proteins. Hence, SDS it is not suitable for protein samples that are required to retain their 
functionality. Shifting the charge of proteins may be achieved by the covalent attachment of charged 
groups or by driving the pH further away from the isoelectric point or both. I was aiming primarily for 
a somewhat alkaline pH, allowing most proteins to be deprotonized and have net negative charges. 
However, this strategy is limited since at some extreme point it would interfere with the integrity of 
the protein and dye molecules. Another guiding principle during my work is to keep conditions as 
simple as possible. I established the electrophoresis buffers in native gels, followed by testing them for 
immunohistochemistry on optically cleared brain slices. Since applying electrophoresis to drive dyes in 
whole mount tissues had not been previously performed, I had to tackle the problem by obtaining 
more experience in native gel electrophoresis. As a start, I used a commercial native gel electrophoresis 
protocol and re-evaluated the importance of each component step by step. I eventually excluded 
components that seemed to have no influence on electrophoretic mobility. 
The original commercial protocol (Invitrogen, NativePAGE™ NOVEX® Bis-Tris Gel System) describes a 
specific cathode and anode buffer. These two buffers are essentially the same based on a 50 mM 
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BisTris and 50 mM Tricine salt system at pH 6.8. The only difference is that the cathode buffer contains 
0.02% G-250. 
As samples I used proteins. BSA conjugated to the Alexa-647 fluorophore served as a loading control 
and as a tool to get a better idea about the electrophoretic mobility in native gels. This was done by 
adding BSA at three subsequent time points. The first time point was at the start of the run, the second 
and third were 2 and 4 hours later respectively. Alexa-647 gives additional negative charges to BSA, 
hence improves mobility. Additionally to BSA, I used an anti-amyloid-beta antibody (β1) [59], 
conjugated to 3 different fluorophores and to none. The first fluorophore, Alexa-594 (kindly provided 
by Paolo Paganetti), carried one net negative charge, the second and third (DY-677 and DY-678, 
Dyomics) carried two and three negative charges (kindly provided by Rainer Kneuer, NIBR, Basel) 
respectively.  
 
I used these various additional charges to assess their influence on electrophoretic mobility. Note that 
the conjugation method of the fluorophores was N-hydroxy-succinimide ester-based, nonspecifically 
linking fluorophores to primary amines. This results in a range of various fluorophore-protein ratios 
within a sample. An additional sample was anti-GFP antibody conjugated to Alexa-594. By loading this 
protein and comparing it to β1 conjugated to Alexa-594, I wanted to understand the influence of a 
given fluorophore on the electrophoretic mobility of different “carrier” proteins. There must be at least 
some difference between the molecular weight of the anti-GFP antibody and β1 antibody, while the 
same dye is conjugated to them. The exact size of the GFP-antibody is unknown. 
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My first question was the following: since the composition of the commercial cathode and anode 
buffer are the same, except that G250 is added to the cathode buffer, I wanted to determine whether 
G250 is necessary. G250 is a negatively charged dye molecule with a physiological isoelectric point that 
is used to stain the migration front and to coat proteins with negative charges [70, 71]. Coating proteins 
with negative charges allows them to migrate better. However, I aimed to avoid introducing the G250 
dye into tissue. Arguably, coating and staining all proteins with a colorful dye in any future tissue 
sample, seemed to be counter-productive idea. Further, it would require additional testing to 
determine if G250 coating interferes with antibody-epitope binding. Guided by the principle to use the 
simplest but best buffer, I wanted to see whether adding G250 makes any difference (Fig. 22). As 
shown in Fig. 22, there is no obvious difference in the migration fronts of the protein samples with and 
without G250. The conclusion from this experiment was that G250 can be excluded without any major 
concerns. One can further see in these gels the electrophoretic mobility of the loaded samples. Since 
the gel is a gradient gel (3-12%) and getting denser towards the bottom, the three BSA samples do not 
show migration distances proportional to their respective incubation time. In fact, with increasing gel 
density, that is with smaller pore-size, major differences in sample mobility occur. This suggests that 
also in hydrogel embedded tissues the porosity might have a major importance in dye-electrophoresis. 
The migration fronts of 3- and 5-hours BSA samples (Fig. 22 right gel) show, that 2 hours additional 
incubation results in almost the double in migration distance - even in the medium dense parts of the 
gel. Based on these results we expect run times to be in the range of hours for HITS in tissue, which 





The mobility of the β1 antibody is clearly improving with the increasing net negative charge, largely 
influenced by the fluorophore attached. As the same protein is conjugated with the same succinimide 
ester-based conjugation chemistry, a similar distribution of labeled primary amines is to be expected. 
Hence, the migration fronts are representative of the improvement in electrophoretic mobility due to 
the respective fluorophores. It is also clear from these gels that the β1 antibody without fluorescent 
labeling is very slow when it comes to iontophoresis. Assuming the anti-GFP antibody and the β1 
antibody are similar in size, the fact that the GFP antibody is migrating faster when conjugated to alexa 
594 suggests that most likely there are more amine groups carrying fluorophores. This suggests that 
the additional charges have a stronger effect on electrophoretic mobility than size difference between 
antibodies. However, in order to confirm this further tests would be necessary, which are beyond the 
scope of this experiment. 
Figure 22. Native PAGE for testing the influence of the cathode-buffer G250 additive in commercial 
native gel protocols. In the left gel the commercial native gel and respective protocols were used. 
In the gel on the right side, G250 was excluded. Besides having a visible migration front with G250 
(left, arrows), no major effect was seen. Note in the left gel, due to an electrical contact problem 
of the electrophoretic chamber, the 5-hour BSA-sample also ran for 7 hours. The far-left lanes are 
loaded with a commercial protein ladder. Lanes from left to right: protein ladder, BSA-Alexa 647 
with G250 run for 7 hours, BSA-Alexa 647 run for 7 hours, BSA-Alexa 647 run for 5 hours, BSA-Alexa 




The tris-glicine buffer is widely used for isotachophoresis. I compared this buffer to the commercial 
bis-tris-tricine buffer at pH 7.5 (Fig. 23). Without doubt, the tris-glicine buffer is inferior to the bis-tris-
tricine buffer in terms of electrophoretic mobilization of proteins. 
 
 
In addition to introducing negative charges by chemical ligation of fluorophores, increasing the pH of 
the buffer should deprotonate putative protonated carboxyl groups in the antibodies. By these means, 
the net charge of the dyes can be further pushed towards the negative, hence improving 
electrophoretic mobility. Normally, a too alkaline pH would denature proteins. pH 8.5 seemed to be a 
reasonable compromise widely used in some immunohistochemical protocols; still, one should assess 
the functionality of the binders under such buffer-conditions (see later in this section). I tested this by 
making a tris-tricine buffer (50 mM tris and 50 mM tricine in water), titrated to pH 8.5. Note, the 
commercial bis-tris-tricine buffer pH 7.5 is buffered by bis-tris, for which pH 8.5 is out of the buffering 
range. Hence, I changed from bis-tris to tris base. This alteration, changing to tris-tricine pH 8.5, 
resulted in a slightly greater migration of the migration fronts and improved separation of the markers 
Figure 23. Native PAGE to test the difference in electrophoretic mobility of proteins when run in 
the commercial bis-tris-tricine (left) or tris-glicine buffer (right) at pH 7.5. The far-left lanes are 
loaded with a commercial protein ladder. Lanes from left to right: protein ladder, BSA-Alexa 647 
with G250 run for 7 hours, BSA-Alexa 647 run for 7 hours, BSA-Alexa 647 run for 5 hours, BSA-Alexa 




in the ladder-lane (Fig. 24). We also tested the mobility of an alexa-647 (one negative charge) 
conjugated IgG Fab-fragment. As expected, due to its three-fold lower molecular weight compared to 
full-length antibodies, the Fab fragments migrated significantly further/faster. 
 
Concluding the experiments with native gels, the most promising candidate for HITS in tissue was the 
tris-tricine buffer at pH 8.5. We generally refer to this tris tricine buffer as TTB. 
When staining hydrogel embedded tissue, the density of the tissue-hydrogel hybrid will most likely be 
constant with some minor variations. However, we tested our buffers mostly in gradient gels. To get 
an impression of electrophoretic mobility in a non-gradient native gel, we prepared a similar run in TTB 
pH 8.5 in a 6% polyacrylamide gel (Fig. 25). The bands in this gel migrated significantly less in 
comparison to the gradient gels but showed similar relative migration distances. The lanes loaded with 
the different versions of β1 antibody showed a gradual improvement in electrophoretic mobility, as 
the fluorophores carried more charges. Also, since this gel had homogeneous porosity, the 2-hour 
temporal displacements of the BSA samples resulted in proportional migration distances. In general, 
Figure 24. Native PAGE for comparing the electrophoretic mobility when using the commercial bis-
tris-tricine pH 7.5 (left) and custom tris-tricine buffer pH 8.5 (right). In an additional gel the mobility 
of a alexa-647 conjugated Fab fragment was tested. The far-left lanes are loaded with a commercial 
protein ladder. Lanes from left to right: protein ladder, BSA-Alexa 647 with G250 run for 7 hours, 
BSA-Alexa 647 run for 7 hours, BSA-Alexa 647 run for 5 hours, BSA-Alexa 647 run for 3 hours; run 




this latter homogeneous gel suggests that in a retention medium with similar porosity, about 7 hours 
of electrophoresis are required for 1-2 cm of migration at 20 V. 
 
 
In order to use some buffer for HITS, it should be compatible not only with electrophoresis but also 
with immunohistochemical staining.  To test this, I compared different buffers for immunofluorescent 
staining (Fig. 26). I used 250 µm thick cleared brain sections from APP/PS1 transgenic mice harboring 
amyloid plaques[56]. I stained the sections with the β1 antibody in TTB buffer at pH 7.5, 8.5 and 9.5. 
Increasing pH in this range had no obvious effect on antibody staining. The TTB buffer at pH 8.5 proved 
to be compatible with immunohistochemical staining in various settings of optically cleared tissue, 
spanning different tissues in different animal species, as well as cell cultures, including various 
antibodies (not shown).  
 
Figure 25. Native PAGE in a 6 % 
polyacrylamide gel. The proteins migrate 
significantly less compared to 3-12% gradient 
gels. The  2-hour temporal displacements of 
the BSA samples show proportionally 







Figure 26. Fluorescent immunostaining in tris-tricine-buffer at different pH values. Amyloid plaques 
stained β1-antibody in cleared APP/PS1 transgenic mouse brain slices at pH 7.5 (A), pH 8.5 (B), pH 
9.5 (C) and control without antibody at pH 8.5 (D). Brains were embedded in 4% acrylamide and 







Whole-mount mouse brain staining with HITS 
 
After the HITS gadget and electrophoresis buffer were established and operational, I started testing 
HITS by targeting β-amyloid plaques in the APPPS1 mouse model. We chose this model because 
amyloid plaques are abundant and stable, and we had large amounts of reliable recombinant 
antibodies. A reason of equal importance was that the plaques can be stained with an array of small 
molecules too. Small molecular dyes served as an additional experimental paradigm to test and as 
putative positive controls. 
I will describe how to setup a HITS run with the 3D-printed second-generation device. Some of the 
steps including how to set up the agarose-paraffin sandwich for the first HITS version with was 
provided previously. In general, results with the first and second-generation HITS devices were 
indistinguishable; hence, I will focus on the newer and simpler method. 
Setting up a HITS run requires two major steps with additional sub-steps. The first step is to cast the 
acrylamide plug that fits into the chambers. After the plugs are ready, the same chamber can be re-
used multiple times provided the same dye or dyes are used. The second major step involves setting 
up the individual runs.  
Casting the acrylamide plugs takes approximately 30 minutes. Each chamber of a chamber-pair has 
two openings connected by an L-shaped tube (Fig. 20). The opening where the acrylamide will be cast 
is closed with a lid on each chamber. The lid on the dye-loading chamber-side features a small 
protrusion, creating an impression in the acrylamide plug. This impression in the acrylamide plug will 
accommodate the dye-agarose mixture. On the opposite side, a piece of filter paper (BioRad, Thick 
Blot paper, 1703956) is inserted in the opening, just in contact with the lid. This step is important, 
because the filter paper provides a non-sticky contact surface for the tissue. 9 ml of 10 % 
acrylamide/bis-acrylamide mixture is cast into each chamber. The chambers are then turned to stand 
on the lid attached just shortly before, so that the plugs polymerize on the designated surface. 
Polymerization takes approximately 20 minutes. 20 ml acrylamide mixture contains 8 µl TEMED, 200 
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µl 10% APS in water, 15 ml TTB at pH 8.5, 5 ml 40% Acrylamide/Bis-Acrylamide. After the gel is 
completely polymerized, the lids can be detached, and the chambers are ready for multiple rounds of 
HITS. 
Setting up an individual HITS run starts from preparing the chambers with the acrylamide plugs and 
proceeds until starting the electrophoretic process. The following materials are required: 
- ~200 ml TTB buffer pH 8.5,  
- liquid 1% low-melting-agarose in TTB buffer pH 8.5 (LMA) in a 37 °C water bath,  
- charged dyes 
- the cleared sample pre-washed at least 3 times in 20-50 ml of TTB pH 8.5  
- vacuum grease 
- mineral oil (for avoiding the tissue to dry out and to isolate the tissue from buffer trapped 
around the tissue, it can be excluded too) 
Setting up a run step-by-step: 
1. Dissolve the concentrated dye in 600 µl of LMA.  
Note 1: the volume of LMA depends on the volume of the impression in the dye-loading 
acrylamide plug and the size of the sample. 
Note 2: The dye-volumes I usually dissolve are 10-20 µl. If the stock solution is less 
concentrated and significantly larger volume of dye is required, then the concentration 
and amount of LMA needs to be adjusted. 
2. Have the tissue sample ready on a tissue paper. Position the dye-loading chamber so that the 
loading side of the plug is even and facing upwards. 
3. Pipette the LMA-dye mixture on into the impression on the acrylamide plug. Immediately after 
this, put the tissue with the flattest surface into the liquid LMA-dye. This needs to be done 
relatively quickly since the LMA hardens in 10-30 seconds. 
70 
 
4. After the LMA is hardened, test insert pieces of different thickness on the chamber. Choose an 
insert piece with a thickness, so that the tissue emerges approximately 1 mm above the surface 
of the insert piece. 
5. Smear vacuum grease on the plastic surfaces – that of the two chamber blocks and the insert 
piece - which will touch. 
6. Place the insert piece on the dye-loading chamber block – which is still facing upward. 
7. Inject 100 – 300 µl of mineral oil around the sample. Be careful not to inject on the tissue 
surface facing upwards, since this may block electric conductance. 
8. Place the second chamber-block where the acrylamide plug is covered by a filter paper over 
the insert piece and tissue. Fix the three plastic pieces together with a pair of bolts. The HITS 
chamber is now assembled. 
9. Turn the assembled HITS chamber on the bottom flat surface, so that the buffer inlets face 
upwards and fill the chamber-blocks with ~20 ml of TTB pH 8.5. 
10. Plug in the electrodes. 
11. Switch on the power supply with the settings of 20 V constant voltage for as long as the dyes 
and tissue require it (e.g. 2-10 hours). 
 
Comment: I established 20 V constant voltage as the running setting for HITS early on. I observed, that 
higher voltages exert a force on tissue pushing it towards the anode resulting in tissue deformation. 
At 20 V this phenomenon was barely recognizable; thus, I used this as a standard. 
 
12. After the run is finished, discard the buffer and disassemble the chamber. Put back the tissue 
into a tube with TTB buffer.  
 
Before imaging, the following steps are required: 
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13. After washing the sample in TTB for a few hours, change TTB to PBS for a few hours. Change 
PBS once. It is also possible to directly go into PBS. This depends how efficient the 
electrophoresis is in extracting superfluous dyes. 
14. Equilibrate the optical density of the sample with RIMS[19], by adding first 2 ml of RIMS for 12 
hours at constant slow shaking, followed by decanting the fluid and adding 4.5 ml of fresh 
RIMS followed by a few hours of constant slow shaking. 
 
Imaging was done with a custom-made single plane illumination microscope (mesoSPIM) in 
collaboration with Fabian Voigt and Fritjof Helmchen (HIFO, University of Zurich, Zurich, Switzerland). 
Some recordings were done with commercial confocal microscopy (Leica SP5 and SP8). 
 
After testing various settings for electrophoresis in HITS for whole-mount APPPS1 mouse brains, we 
learned that staining with small molecules is very straight forward and robust (Fig. 27). We also 
observed that antibodies retain their functionality to bind their epitopes. However, on the time scale 
tested (< 10 hours), antibodies label only superficial epitopes (Fig. 27B). In our hands, staining β-
amyloid plaques with negatively charged luminescent conjugated polythiophenes (LCP) [62] resulted 
in homogeneous labeling of β-amyloid plaques throughout the brain after 2 hours of HITS (Fig. 27C, 
16D). Similarly, HITS with the positively charged nuclear dye diaminido-phenylindol (DAPI) results in 





To confirm that the whole-brain HITS with LCPs results in a homogeneous stain I did the following 
experiment. I cleared two APPPS1 positive mouse brains. One I stained with LCP-HITS, one was left 
unstained. I then cut sections with a vibratome from both whole-brains and imaged them in a 
stereomicroscope (Fig. 28). The unstained negative control did not show any plaques (Fig. 28A), which 
visible by their autofluorescence is a microscope with a sensitive detector (Fig. 27A). In order to test 
the utility of the protocol, I stained the same negative control with an established and published 
passive staining protocol [62], which after re-imaging revealed numerous plaques (Figure 30B). The 
HITS-stained brain slices cut in the sagittal plane showed many labeled plaques both in superficial and 
deep regions of the brain (Figure 28C). After imaging the slice, I stained the same slice with the same 
established and published passive staining protocol as for the negative control. In theory, by applying 
an established passive staining protocol I should be able to reveal plaques that were not stained with 
HITS, but were stained with the passive protocol – highlighting what a HITS-stain missed. Re-imaging 
this slice after passive re-staining showed essentially an identical picture (Figure 28D), with the same 
A C B 
Figure 27. Comparison of HITS with antibodies in 2 hours and small molecules in 2 hours in a whole-
mount mouse brain in sagittal view. The same APPPS1 transgenic mouse brain was optically 
sectioned in the sagittal plane without staining (A), after staining with β1 antibodies (B) followed 
by staining with luminescent conjugated polythiophenes (C). Note that plaques are visible in the 
non-stained (A) due to their faint autofluorescence, which is enhanced by adjusting the dynamic 
range of the viewer in order to see the background of the image. Due to re-mounting of the sample 
the optical sections are not completely identical. 
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plaques labeled before and after passive staining (Fig. 28E and F). This finding suggests that when the 
conditions for a certain combination of hydrogel-embedded sample and a dye are met, homogeneous 
staining throughout the whole sample volume is possible. The numerous labeled amyloid plaques 






Figure 28. Validation of HITS with LCPs in slices from whole-mount APPPS1 mouse brains. A 
midbrain slice from a whole brain not stained with HITS before (A) and after (B) passive LCP 
staining. Median-sagittal slice from a whole brain stained with LCPs by HITS before (C) and after 
(D) passive LCP staining. Thalamic areas in brackets (C and D) are magnified before (E) and after (F) 
passive LCP staining. Magenta arrows point to exemplary plaques visible in both images and serve 
as landmarks for orientation. Slight differences between E and F are mostly due to a slight shift in 




Figure 29. Three-dimensional rendering of whole-brain stacks from APPPS1 transgenic mice stained 
with LCPs by HITS. The brain of the 170 days old mouse (A) shows significantly fewer plaques than 






Ultrasonic standing waves (USW) were generated with a simple 1.7 MHz ultrasonic humidifier (~20 W) 
by placing it in a glass cuvette. Tissue samples were mounted on a plastic tube with rapid glue. The 
cuvette was containing a mixture of DAPI and To-Pro-3 at 1:10.000 and 1:1000 dilutions respectively 
(Fig. 30).  
 
 
1 mm think hydrogel embedded and SDS-cleared human lymph node slices were treated for either 5, 
15 or 30 minutes. Respective controls remained in the dye solution for the same periods of time in the 
same position of the cuvette but without sonication. This experiment resulted in a robust 
enhancement of dye penetration and staining intensity already at 5 minutes sonication, further 
increasing at 10 and 30 minutes throughout the entire depth of tissue (Fig. 31). 
Figure 30. An ultrasonic humidifier used for sonicating tissue in a standing wave setting. DAPI-
aggregates (yellow cloud in the buffer) and aligns in the pressure nodes of the sonication field. 
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Staining intensities decreased at the end of the stacks (deep in the slices), which most likely was the 
result of signal attenuation due to light scattering of the tissue. The narrower staining depth with DAPI 
compared to To-Pro-3 supports this, as shorter wavelength excitation and emission is more scattered 
by tissue (DAPI excitation 405 nm, To-Pro-3 excitation 633 nm). 
Because temperature increases in the sonication field which is however very difficult to measure, we 
wanted to be confident that the observed effect on staining efficiency was temperature independent. 
For this we conducted an experiment where we sonicated both the treated and the control samples 
Figure 31. DAPI and To-Pro-3 staining-depth in human lymph node slices with (US) and without 
ultrasonic standing waves (CTRL). To-Pro-3 nuclear staining at 10 μm and 650 μm depth, and an 
orthogonal re-slice of the corresponding stacks (A).  Both DAPI and To-Pro-3 staining show a 
multi-log increase in staining intensity throughout the slice at the three incubation times (B) (10 





but blocked the pressure waves from entering the control sample by a small metal capsule. The metal 
capsule was permeable to the surrounding buffer perpendicularly to the axis of the pressure waves to 
ensure unlimited contact with the staining solution. After sonicating the samples with and without 
metal encapsulation the metal capsule clearly eliminated the sonication effects and dye penetration 
was largely impeded (Fig. 32). 
 
 
After these initial results I designed and tested a plethora of devices and experimental paradigms. 
These experiments are still ongoing. A detailed description of designs can be found in the patent 
application [US Patent Office, Application number 62/695,477]. 
  
Figure 32. Blocking of sonication with a metal cage. To-Pro-3 staining depth in human lymph node 






Tissue clearing with CRYSTAL 
 
In the past few years various tissue clearing approaches have emerged that homogenize the refractive 
index in large tissue-samples and thus render samples optically transparent. Each of these methods 
has advantages and disadvantages that span variables of throughput, complexity, degree of achieved 
transparency, retention of proteins, tissue swelling or shrinkage and, retention of fluorescence of 
reporter proteins.  
In this study we established a CLARITY-based method. CLARITY, one of the pioneering methods in tissue 
clearing proved to be problematic to implement. Our approach to optimize CLARITY was based on the 
observation that the design of the electrophoretic process in CLARITY was inefficient. In order to 
address this limitation, we proposed that efficiency could be enhanced by focusing the electric current 
through the tissue instead of broadly applying current to the buffer in the electrophoretic chamber. 
Establishing a framework to test this hypothesis required the design of multiple prototypes, which 
were largely hand-made and coarsely designed until the optimal configuration was achieved. Tissue 
burning was another obstacle encountered with the standard CLARITY method, which required 
extensive troubleshooting before favorable temperature conditions were established. To remedy this 
problem, I built an in-flow thermostat with a microcontroller allowing for continuous monitoring and 
logging of the buffer temperature with 0.5 °C accuracy. Finally, our clearing settings were 130 mA 
continuous current with a voltage limit at 60 V at 39.5 °C. Depending on the paraformaldehyde 
concentration of the fixative (either 1% or 4%), the clearing of a mouse brain took 2-8 or 16-20 hours, 
respectively. With this approach, we could generate impressive three-dimensional images of various 
murine brain samples. The morphology of the samples was well preserved, even allowing visualization 
of dendritic spines. To a limited extent, we could also introduce immunolabeling into cleared samples, 
however these staining attempts remained to stain superficially only. We were also able to stain 
79 
 
cleared tissue slices (brain and lymph node) with antibodies with classical immunohistochemical 
methods. 
In our experience the batch-to-batch variability of samples has considerable effects on clearing 
performance. We assume that the perfusion-fixation process, the age of the mouse and sample 
storage time in SDS prior to clearing play a major role in this variability. In the worst case, this results 
in difficulties of clearing in samples with heavily myelinated structures. However, extending clearing 
times results in over-clearing of superficial tissue-layers. Over-clearing and the loss of protein epitopes 
are pitfalls in the electrophoretic clearing approach in general. In our study however, this did not prove 
to be an unsurmountable problem. Nevertheless, the clearing pipeline – including transcardial 
perfusion – should be calibrated in pilot runs for any given project. By doing so we produced multiple 
dozens of samples with consistently good transparency. 
Our final CRYSTAL prototype was very efficient at clearing tissue; however, the device was not easy to 
use. Accordingly, we designed a small CRYSTAL chamber with Michael B. Smith (Novartis, Cambridge 
MA, USA), which could be 3D-printed. It was designed in a way that the sample could be easily removed 
from the chamber and assessed. The design can also be easily modified to accommodate larger 
samples, further it is easy to parallelize multiple setups. These 3D printed devices are routinely used in 
our laboratory nowadays. 
In the last years commercial solutions based on the CLARITY method appeared on the market, however 
reviews of these machines in the scientific community are mixed. Some internationally renowned 
groups tested the various tissue-clearing option available and decided to implement the CRYSTAL 
system in the end. The biotech company (ClearLight Biotechnologies LLC.) invested in licensing the 
CRYSTAL technology, too. After adapting the system to their requirements, they achieved 
unprecedented results in clearing tissue biopsies (homogeneous clearing of 2x5x5 mm disks in 30 
minutes). The unbiased assessment of the CRYSTAL technology by scientists without any conflict of 
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interests suggests, that the CRYSTAL technology is indeed powerful. Nevertheless, the aforementioned 
pitfalls apply and need to be considered when working with it. 
 
Tissue staining with HITS 
 
The recently emerging techniques of high-quality whole-mount tissue clearing and imaging herald a 
new era in histology. Standard histology encompasses methods which are low-throughput, low-scale 
and involve subjective assessment. By 3D histology, the field is evolving rapidly due to high-
throughput, large-scale and sophisticated digital methods requiring less human supervision.  Tissue 
clearing allows us to image sample blocks as a whole in the range of centimetres, while retaining 
cellular resolution. High-resolution fluorescent laser microscopy methods like confocal microscopy or 
multi-photon microscopy have limited throughput. However, light- sheet microscopy allows for 
significantly higher imaging throughput, thus making the microscopic acquisition of large volumes and 
whole-mount organs feasible [10, 37]. Light-sheet microscopy has limitations too. For example, image 
quality depends on local variations of tissue transparency and optical density, which can vary 
considerably in large tissues. Further, light-sheet microscopy is in most cases non-isotropic in the 
sense, that the axial resolution and lateral optical resolution do not coincide. The reason for this is that 
the axial resolution is defined by the spacing of optical slices and the optical-slice thickness (that is the 
light-sheet thickness), while the lateral resolution is truly optical. It is difficult to achieve a 
homogeneous light-sheet thickness below 3 micrometers.  
With increasing sample volumes, the introduction of molecular labels becomes challenging. The 
standard low throughput staining protocols applying passive diffusion represent a rate-limiting step. 
In our view, the options for improving throughput by modulating passive diffusion is limited to 
adjusting the porosity of the sample and the size of the dye, which are nevertheless important handles 
to explore [16, 25]. However, these options have to be tested and optimized for each epitope and 
tissue type. Recently, new approaches such as this study have been published, which address the 
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throughput limitations of whole-mount sample staining by applying external forces to improve dye-
penetration[23, 25].  
Histochemistry by iontophoretic tissue staining (HITS) utilizes an electric field to exert force on charged 
molecules. The framework of HITS is based on spatially focused isotachophoresis, and it includes the 
main components of an isotachophoresis system, namely the analyte, the buffer, the retention 
medium in an electrophoretic chamber, and a power supply. In HITS, the analytes are the respective 
molecular labels; the retention medium is the tissue sample. We established a suitable buffer system 
by testing different salt compositions in native gels and with immunohistochemistry. Our tests 
indicated that a simple tris-tricine buffer system at pH 8.5 was optimal. In addition, we learned through 
native gels that the electrophoretic mobility of proteins was improved when fluorophores with net 
electric charges were covalently attached. The most challenging aspect of HITS was the design of an 
electrophoretic chamber. After various trials, we finally came up with a user-friendly chamber design 
for 3D printing. We tested our setup in the APP/PS1 mouse model of cerebral amyloidosis, where we 
could compare small molecular dyes (~1 kDa) and antibodies (~150 kDa) binding the amyloid-β 
aggregates. Our results indicate that with small molecular dyes we were able to stain the entire brain 
homogeneously within 2 hours. At the same time our tests with antibodies showed only a superficial 
stain in 2 hours. Essentially, the antibody stain is distributed along the tissue surface in alignment with 
the electric field vector, however, only in superficial layers of the tissue. The likely reason for this being 
that the significantly larger antibodies have difficulties in penetrating the tissue. Other small molecular 
dyes, such as DNA binding dyes (DAPI, To-Pro-3) are also successfully used in the setting of HITS. 
Another aspect which might hinder antibody penetration is the binding kinetics of the antibodies. This 
hypothesis postulates, that if there are abundant epitopes the binders will “spend time” on binding 
and dissociating from and to the epitopes. This would slow effective diffusion additionally to the 
mismatch between the hydrodynamic radius and tissue porosity. In the future, we will address these 
problems by prolonging incubation times, increasing tissue - pore size and by modulating the electric 
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field vector in combination with sonication. Further, we think that by tuning antibody binding kinetics 
during the staining process by switching the buffer pH, we could improve whole-mount staining too. 
The only published method showing active facilitation of whole-mount staining is also electrophoresis 
based as shown by Kim and colleagues[23]. A comparison between HITS and the stochastic 
electrotransport method is possible only to a limited extent. The main reason is that the feasibility of 
a new method is only proven when it is reproduced. There is no work published which reproduces their 
results, except from two publications within the same laboratory. Further, a device based on that 
technology is promised to be marketed, but it has been due for more than a year (Smartlabel, 
LifeCanvas Technologies). However, these developments are also too recent. Constructing a custom-
made device such as HITS is very simple and safe, whereas the stochastic electrotransport model is 
more complex and may be dangerous, since it utilizes 200 V - ten times as much as HITS. The major 
advantage to HITS is the successful staining with antibodies. It should be noted that this is only 
achieved with ‘industrial’ amounts of dyes. Essentially, only one antibody stain in a single sample was 
presented in the paper, which required an entire vial of commercial antibody. The nuclear stains were 
achieved by extensive amounts of stock solutions, which may significantly impede the applicability of 
this method in situations where statistically meaningful sample sizes are required. It remains to be 
seen whether the scientific community can reproduce these results. This work shows how we 
successfully stained more than 50 mouse brains with LCPs via HITS. However, for a broad applicability 
further improvements are necessary. In my view, the limited success with antibody stains with HITS is 
not because of the lower amounts of antibodies (10-20 μg/brain) used. My argument is based on the 
premise that if successful staining were a question of the amount of antibodies, I would expect a 
superficial-to-deep gradient of the fluorescent signal in the tissue. However, we only see a bright 
superficial layer of fluorophores (Figure 27B). This suggests a problem of dye penetration or retention. 
The reason for this may be either the limiting tissue porosity, or the arrest of dyes by prolonged 
paratope-epitope association and dissociation processes, or both.   The main advantage of HITS lies in 
its simplicity and in entrapping of the dyes in agarose. It is easy to parallelize multiple setups and 
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samples can be exchanged between runs within minutes, which enables parallel and high-throughput 
handling. The entrapment of dyes in low melting agarose allows for a highly concentrated dye front, 
which may provide a useful means to control the amount of dyes consumed for a sample. 
The development HITS and similar methods fits into the evolution of methods in histology. Previously, 
a multitude of protocols and stains were invented to visualize various molecules, proteins or nucleotide 
sequences in tissue slices. We anticipate that most of these stains can soon be rapidly introduced into 
large tissue blocks by HITS or similar methods. Together with tissue clearing and large-scale 
microscopic imaging, the combination of these methods will yield an unprecedented increase in 
morphological data. Essentially, we can image all the cells of a mouse brain within some tens of 
minutes. Through these methods high-resolution data can be acquired, while datasets retain their 
reference to the overview of the whole sample. In other words, we will soon have access to whole-
organ datasets, where starting from the overview image of the organ one can easily zoom into a region 
of interest until cellular resolution.  
The option, that the entire structure including all cells in an organ can be acquired, represents a major 
methodological leap in acquiring knowledge about biological systems. Intriguingly, despite the 
stunning 3D images generated it had become quickly evident, that in most cases our brain is incapable 
of processing these large amounts of complex data. This entirely new way of doing histology is 
uninterpretable without the help of unbiased computational analyses. We foresee a major challenge 
in the design of algorithms that are sufficiently flexible to cope with external variables, yet efficient in 
handling terabytes of data. By external variables we refer to variables which are independent of the a 
priori tissue structure. There are multiple sources of such variability spanning individual biological 
differences to technical artefacts, which can be random and more challenging to resolve. In fact, we 
have observed possible sources of technical variability during every step of tissue processing (from 
perfusion to staining) and during imaging (air bubbles, dust, tissue damage). 
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Whole-organ histology is in the early phases of its development, with multiple competing methods for 
each step of the process. Notwithstanding the excitement of the scientific community, there is 
insufficient experience and quality standards are lacking. The major challenges are the introduction of 
molecular labels into whole-mounts and the lack of robust, flexible and user-friendly software to 
analyze these types of datasets. I hope that by introducing HITS, scientists in the field can utilize and 
improve this method to further advance the field. 
After testing various light – sheet microscopes over the past years, we decided to build our custom 
selective plane illumination microscope (SPIM). For this we teamed up with Fabian Voigt and Fritjof 
Helmchen (HIFO, University of Zurich, Zurich, Switzerland), who designed a SPIM. This was perfected 
through multiple iterations with the help of our feedback and gave rise to the mesoSPIM project. The 
mesoSPIM spans a resolution range of 1-10 μm/pixel with respective fields of view of approximately 2 
mm – 25 mm. Sample loading is very convenient. The mesoSPIM promises to become a great success 
as already eight machines were built in different countries. 
Data management and analysis depend largely on the scientific question. Nevertheless, in case of 
whole-brain organ acquisition data management poses a considerable challenge. This challenge 
mandates close collaboration between biomedical- and computer scientists. Recent advances in 
machine learning, especially in deep learning and convoluted neuronal networks, will significantly 
improve our abilities to handle and process these datasets. In the last years, libraries for neural 
network programming have expanded and the scientific community has begun to develop platforms 
that makes these tools more accessible for non – specialists. These will likely be having an impact on 
the field. 
I am convinced that once conditions have been optimized for rapid and reproducible tissue clearing, 
staining, imaging and analysis, this technique will become a major part of standard microscopic 









Cancer metastasis detection in lymph nodes 
 
Cancer is one of the leading causes of death in many industrialized countries[72, 73].  Correctly 
diagnosing a cancer and quantifying the degree to which it has spread is the fundament of providing 
appropriate care for cancer patients. Staging is used to describe the extent and severity of an 
individual’s cancer. It routinely is consists of describing location and size of the primary tumour, lymph 
node involvement and any presence of distant metastasis. Accurate staging of cancer is crucial in most 
types of cancer[74], as prognosis and treatment are highly dependent of cancer stage[75-78]. In many 
types of cancer, including the most common ones such as breast cancer, melanoma, colon cancer and 
non-small cell lung cancer, the absence or presence of lymph node metastasis will result in categorizing 
the patient in a different cancer stage with its respective prognostic consequences and therapeutic 
recommendations (2017, NIH National Cancer Institute). Hence, a precise histopathological 
examination – representing the benchmark for the staging of lymph nodes – is essential. 
There are various protocols on the histopathological examination of lymph node biopsies across 
Europe (e.g. sentinel lymph node in breast cancer)[79]. A standardized approach with a thin sectioning 
protocol with the aim of identifying all macrometastases (metastatic lesions >2.0mm) has been 
suggested on multiple occasions[80, 81]. Yet even in thin sectioning protocols with intervals of 2mm, 
a considerable degree of uncertainty remains in the detection of micrometastases (defined as <2.0mm 
but >0.2mm). 
The significance of lymph node micrometastasis remains controversial and is yet to be determined for 
many forms of cancer. In a recent study, risk of recurrence in gastric cancer was established to be 
significantly higher when lymph node micrometastasis was present (N1mi) compared to patients 
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without lymph node metastasis (N0)[82]. In breast cancer, multiple studies were conducted on this 
exact subject. The conclusions varied substantially - some showed no difference in overall survival and 
progression-free survival between N0 and N1mi patients, whereas others showed worse overall 
survival, progression-free survival or disease-free survival in N1mi patients compared to N0 
patients[83-87]. Clinical studies determined micrometastases to be a negative prognostic factor in 





Therapeutic approaches in Alzheimer’s disease 
 
Alzheimer’s disease is a slowly progressive and irreversible neurodegenerative disease leading to 
dementia with complete disability and death. AD represents a major socio-economic challenge to aging 
societies, as AD’s incidence increases with age[91-93]. In our enlightened - hypercognitive as some 
refer to it - society most of the core values of an individual are considered to be lying within its cognitive 
abilities[94]. The extreme manifestation of cartesian “Cogito ergo sum”-ism was when thousands of 
individuals with dementia or mental disability were systematically murdered in the Third Reich[95]. 
Despite the turn of tides, the thought of being affected by AD is for most of us very frightening[96], as 
AD gradually leads to the deterioration of an individual’s personality and dignity. Further, our more-
and-more complex way of functioning in everyday life is impossible to cope with once cognitive abilities 
decline. Hence, there is a massive demand for an effective therapy for AD. 
AD can be genetic, but most frequently it is sporadic without a known cause[97]. In the course of AD 
there is a continuous neuronal loss leading to brain atrophy. Pathological hallmarks of AD are intra-
neuronally aggregated hyperphosphorylated tau protein, so called neurofibrillary tangles (NFT), and 
extracellular AβP (Fig. 33A-E)[98]. Both of these protein aggregates are amyloids. Amyloids in general, 
are very stable fibrillary protein aggregates with cross-β-sheet structure[99, 100]. Amyloids are 
polymers of a single misfolded (towards a β-sheet structure) protein entity, which in its native form is 
physiological. The progression of the disease shows a relatively stereotypic clinical and pathological 
sequence. After a presymptomatic stage the symptoms start with light short-term memory 
disturbances and gradually progress into complete dementia[101, 102]. In parallel, the pathological 
sequence shows a stereotypic progression of both NFT and AβP amyloids, however with differing 
spreading routes. NFTs begin accumulating in the entorhinal cortex, followed by spreading through the 
hippocampal and cingulate areas and then further to cortical associative regions (and many subcortical 
regions). At the ultimate stage, NFTs start to accumulate in primary cortical areas with the primary 
visual cortex being the last[103]. At the same time, the accumulation of AβP starts rather in the cortex 
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Figure 33. Hallmarks of Alzheimer’s disease and its pathological staging. Amyloid plaques and 
neurofibrillary tangles with hematoxylin-eosin stain (A,B respectively), with silver impregnation (C), 
and with immunohistochemistry (D,E respectively). Stages of neurofibrillary degeneration from 
entorhinal (left) to primary cortical areas (right). Degree of pathology as shades of magenta. 
Numbers refer to Brodmann areas (F). Stages of amyloid plaque spread according to Thal starting 
from cortical areas spreading towards deep and caudal brain areas (Phase 1-5) (G). Amyg – 
amygdala, Cg – cingulate gyrus, Prec – precuneus, EC – entorhinal cortex, (Adapted from Serrano-
Pozzo A et al 2011, Cold Spring Harb Perspect Med: A-F; Thal DR et al 2002, Neurology: G)  
89 
 
The pathophysiological sequence of AD is not entirely understood. Even the framework of 
neurodegeneration in AD is considerably unclear. For example, it is not clear whether some direct 
neurotoxic product is killing the neurons or they succumb indirectly due to an inflammatory process 
[105], or the direct contributor to neuronal death is vascular pathology-related [106-109], or some 
combination of all of these [110-112].  In the last two decades the more favoured hypothesis pointed 
at AβP being the main toxic actor in the disease, while tau-toxicity provided a major alternative 
hypothesis[113]. The emphasis on AβP is generally referred to as the “Amyloid cascade hypothesis” 
[114-116]. This hypothesis assigned tau-pathology a rather secondary role. Nevertheless, some started 
to focus (again) on tau more recently[107], not the least because the clinical stage of the disease is far 
better correlated with the stage of NFT spread than the degree of AβP, and people with large loads of 
AβP pathology can be asymptomatic [103, 111]. Along these lines some even argued that AβP may 
even be a defence mechanism against injury [117]. In practical terms, therapy trials show a trend-shift 
towards targeting tau-homeostasis [118]. Nevertheless, one of the strongest arguments supporting 
the amyloid hypothesis however is based on some of the hereditary forms of AD. In these early-onset 
genetic forms either the precursor of the amyloid β protein, namely the amyloid precursor protein 
(APP) itself, or enzymes involved in the processing of APP harbour mutations[116, 119]. Any of these 
mutations lead to a disbalance in the metabolism of APP, resulting in extensive amounts of early AβP 
accumulation and AD. In theory, one could still argue that sporadic and genetic AD are only 
symptomatically related but are otherwise different diseases, hence the main cause of sporadic AD 
may still side with the tau protein. Also, conditions leading to dementia may be manifold and result in 
the same pathological phenotype. 
Amyloid-β (Aβ) is a hydrophobic 39-43 amino acid residues-long polypeptide. It is the product of the 
APP after multiple proteolytic steps. Determining steps in the generation of β-amyloid are the β-
cleavage and γ-cleavage of APP, catalysed by the β-secretase and γ-secretase enzymes respectively 
(Fig. 34A)[120, 121]. Once the β-amyloid peptides are produced, they may start to form growing fibrils 
which may form plaques later. Among these various sized β-amyloid aggregates, the oligomeric forms 
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are considered to be the neurotoxic forms [122-124]. These may form in early stages of aggregation 
when single molecules join to form fibrils, or later when longer fibrils break. Related to this, a notable 
phenomenon in amyloidogenic proteinopathies is seeded (or secondary) nucleation. During this 
process small aggregates of misfolded amyloidogenic protein recruit their physiological counterpart to 
misfold and join the aggregate (Fig. 34B)[124-126]. This is believed to be the mechanism by which 
proteinopathies, as AD, propagate and spread in the CNS [126, 127]. 
 
In the last decade, therapeutic candidates for AD were almost exclusively targeting components of the 
β-amyloid pathway (after some unsuccessful approaches intervening with the cholinergic system). 
Therapeutics addressing the β-amyloid pathway explicitly, target either the synthesis or the clearance 
Figure 34. Amyloid – β 
production via the 
metabolism of the amyloid 
precursor protein, APP. APP 
can be proteolytically cleaved 
by either α-secretase or β-
secretase after which either 
amyloid-β or the p3 fragment 
are secreted by γ-secretase 
cleavage (A). The concept of 
templated and seeded 
misfolding, monomer 
aggregation into growing 
structures, and fibril 
fragmentation back into 
smaller entitites (B) (From 
Vardy ER et al 2005, Trends 
Mol Med; Aguzzi A & 




of β-amyloid [120]. Drugs targeting the production of β-amyloid are enzyme inhibitors either targeting 
the effects of γ-secretase or β-secretase. γ-secretase is an enzyme with a broad set of functions, and 
is also contributing to the notch signalling pathway - making off-target effects highly undesirable. Many 
of the clinical trials with enzyme inhibitors were terminated due to adverse effects like elevation of 
serum liver enzymes, some even worsened cognitive performance. Intriguingly, in some cases despite 
lowering β-amyloid loads there was no convincing cognitive improvement raising doubts about the 
amyloid hypothesis or pointing to some missing puzzle in our understanding [128].  However, there 
are still compounds in clinical trial. Therapies targeting the clearance of β-amyloid and its derivates are 
exclusively antibodies and are used as immunotherapies. A plethora of antibodies were designed to 
bind various epitopes on the β-amyloid peptide. Their pharmacodynamic mechanism is understood 
either as exploiting phagocytosis by microglia via Fc-receptors. Alternatively, the “β-amyloid sink” 
theory suggests, that by binding and enhancing the clearance of peripheral β-amyloid in the blood, 
CNS β-amyloid is drained at higher rates out of the CNS to the periphery. Many compounds failed in 
clinical trial due to lack of significant effect or side effects, like meningitis. Some compounds are still 
under evaluation. A comprehensive review and summary of failed and ongoing clinical trials for anti-
AD compounds was provided by Graham and colleagues in 2017 [129] (See table in the Appendix).  One 
of the most recent failed trials was in the case of the antibody adacanumab, which raised high hopes 
before[130]. Potential pitfalls in AD - clinical trials are for example low blood-brain-barrier 
permeability. More importantly however, the lack of good diagnostic markers of early presymptomatic 
AD makes therapeutic intervention at the prodromal phase difficult, which however could exactly be 
the point when interventions could succeed. Addressing this issue, serum neurofilament-level 
dynamics were shown to robustly detect AD in the prodromal phase of familial AD patients recently 
[131].  As a third therapeutic alternative, different from synthesis-inhibition and clearance, some 
compounds interfere with amyloid replication. Some of these compounds stabilize monomeric or 
unfolded forms, others redirect folding[132]. Potentially, some compounds could bind to and thereby 
stabilize larger β-amyloid fibrils, a mechanism which was shown to be the case of prion-amyloid[61, 
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133]. By stabilizing amyloid fibrils, fibril fragmentation and thus the generation of the toxic oligomers 
can be potentially reduced. Further, by interfering with fibril fragmentation the availability of 
amyloidogenic seeds, or “propagons”, is likely to be reduced too. Thus, by the reduction of available 
amyloid seeds secondary conversion and propagation of toxic β-amyloid entities is protracted[134]. 
Such compounds are for example luminescent conjugated polythiophenes (LCP). Beyond what was 
shown for prion-amyloid, such an approach is potentially beneficial in amyloidogenic proteinopathies 
in general. 
While I discussed some aspects which are accepted as pitfalls in developing AD therapies, I did not 
mention one I would also consider, namely the limitations of our disease models. Across the stages of 
developing any drug, a critical step is the extrapolation from pre-clinical data towards clinical drug 
testing. This step carries the inherent problem of working with models (here the experimental animal), 
namely the accurate prediction of effects in the modelled (here the human). This becomes especially 
problematic when the system being investigated is complex, like the brain. I refrain from attempting 
to quantify the difference in degree of complexity between the brains of say, mice and human. 
Similarly to inter-species differences, different methods like murine neuronal cell cultures or cerebral 
organoids, even at hypothetical scales of a mouse brain, would fundamentally lack the organized 
complexity of its modelled (a functioning mouse brain). I would argue, that by simply asking to what 
degree a model resembles the overarching functions of its modelled, gives a good idea how good the 
resemblance between the model and the modelled is. For example, a murine neuronal cell culture is 
far from replicating the various functions of an intact mouse brain. At the same time, cultured liver 
cells, liver-on-a-Chip[135] or a liver organoid but also a lung-on-a-chip[136] are not far from fulfilling 
the functions we assign to real livers or lungs – fundamentally contrasting models of the brain. 
Therefore I would argue, that e.g. a lung-on-a-chip is a far better model than any in vitro model of the 
brain. Steering back to inter-species differences, there is little functional difference between the liver 
or the lung of mice and a human on the organ-level. However, the difference in functionality between 
the human and the mouse brain is vast. It is fair to say - without dwelling on complex phenomenological 
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contemplations- that the difference is not only quantitative (number of neurons or synapses), but also 
qualitative. Taken together, predicting drug effects in the human brain based on the mouse brain can 
pose a challenge. Related to this, an additional and rather CNS-specific challenge of experimental 
modelling resides in the structural heterogeneity of the brain. There is one single axis of symmetry in 
the brain, the midline. Beyond this, the anatomical structures and their functions change drastically 
within a few dozens of micrometers. It is conceivable, that all the various brain regions not only differ 
in their neuronal organization, but also in many additional aspects (astrocytic phenotypes, myelination, 
microglia, gene-expression etc.) creating distinct micro-milieus. It is likely, that these different micro-
milieus react differently to certain interventions. Hence, as a synthesis of these problematic aspects 
and arguments considering experimental CNS models I argue: We ought to understand how drug 
effects unfold within a brain and its heterogeneous structure of one animal species before attempting 
to predict drug-effect across the brains of very different species. In reality however, in most cases such 
studies do not precede clinical trials. When testing AD therapeutics like anti-Aβ compounds, the usual 
read-out are gross quantitative Aβ loads in plasma, cerebrospinal fluid or brain tissue, or individual 
histological brain section mostly from the cortex and/or from the hippocampus[58, 59] (Fig. 35).  
 
My work in this thesis aimed to highlight the problem and the relevance of organ-scale testing of 
pharmacological compounds in the brain. To this end I utilized my improvements in whole-mount 
tissue-clearing and staining on an AD mouse model. I applied three different classes of anti-Aβ therapy, 
an Aβ antibody, a β-secretase inhibitor and a LCP in the APP/PS1 mouse model[56], and quantified 
global and local plaque loads in the brain. I aimed to identify treatment patterns related to the distinct 





Figure 35. Standard analytical tools for testing the effect of anti AD-drugs. Vehicle (A) and anti 
amyloid-β antibody treatment (B) in cortical sections. β-secretase inhibition shown on cortical 
sections with vehicle (C) against treated (D). Biochemical methods for determining the level of APP 
metabolites upon β-secretase inhibition in CSF (E), plasma (F) and brain homogenate (G). Red for 
N-terminal antibody, green for C-terminal antibody.  (Adapted from Pfeifer M et al 2002, Science: 





Clearing and imaging of lymph node tissue 
 
Clearing of human lymph nodes proved to be more challenging than that of nervous tissue. The most 
likely explanation for this is a higher content of birefringent collagen rich fibrous tissue and blood 
residues. Through a multitude of experiments assessing tissue transparency after various treatments, 
we managed to clear 1 mm-thick lymph node slices, stain them with antibodies against CD20 and image 
them with a confocal microscope (Fig. 36). Details of this work can be found in the MSc thesis of 
Alexander von Hoyningen-Huene. Stemming from these results further work is ongoing in order to 
establish this approach on clinical samples. 
 
  
Figure 36. Proof of principle of lymph node clearing and 
imaging. Starting from a whole human lymph node, after 
cutting few thick (1 mm) slices we established a passive 
clearing pipeline by combining chemical and enzymatic 
treatments (from top to bottom: native whole lymph node, 
slicing, slice after SDS-clearing, collagenase II digestion, 
quadrol treatment). After each step the tissue is more 
transparent (A). A scan of a 1 mm thick cleared lymph node 
piece. The sample is stained for B-Lymphocytes residing in 
follicles (yellow circular structures). One can appreciate the 
overview the approach allows for (B). 
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Brain-wide assessment of AD-therapeutics with CRYSTAL and HITS 
 
In order to answer the question whether drugs targeting different molecular steps in the process of 
cerebral amyloidosis (via the β-amyloid protein), result in different treatment patterns, CRYSTAL and 
HITS combined with mesoscopic imaging seemed to be the ideal approach (Figure 37). These 
technologies make it possible to quantify β-amyloid aggregation in the whole mouse brain while doing 
this at a microscopic resolution. By doing so, accurate AβP loads can be assessed regionally, and 
additional readouts can be investigated. For example, by looking at the size and maturation state[62] 
of individual AβP information can be gathered, which is either not accessible by large scale methods 
(e.g. PET imaging), or only at limited scales by high-resolution methods (e.g. standard histology). Such 
information about drugs targeting the CNS is highly valuable for the translation of preclinical studies 
into clinical trials. Essentially, the entire scope of advantages of such information is hard to estimate 
now, since it has not been available yet. My work presented here provides the first analysis of this kind, 
which hopefully will serve as a benchmark. Provided preclinical trials of CNS therapies will set out 
whole-brain microscopic analyses as a standard, much could be learned also about how mouse-brain 
structural heterogeneity translates into human-brain structural heterogeneity. 
Here we applied three types of compounds interfering with AβP biogenesis, a BACE1 inhibitor 
(NB360)[58], an antibody (β-1)[60] and a luminescent conjugated polythiophene (LIN5044)[61] for 90 









The BACE1 inhibitor was applied via food chow, the other two compounds via intraperitoneal injections 
once a week. Brains were harvested 5-7 days after the last treatment, except the BACE1 inhibitor 
where the mice had access to the BACE1 containing chow until they were transcardially perfused. 
I will present the data gathered from these experiments first by discussing observations in individual 
treatments, followed by comparing treatment modalities. 
The amount of data collected by these methods is vast and a comprehensive representation of all 
aspects is challenging. The data spans 6 treatment groups with additionally controls, for these groups 
we utilize three readouts (plaque density, size and maturity) across all the anatomically defined brain 
Figure 37. Tissue processing pipeline with CRYSTAL and HITS to assess AbP loads in whole-mount 
mouse brains. 
Figure 38. Experimental design of the AD-therapy study. Mice are treated for 90 days with a BACE1 
inhibitor, an antibody or an amyloid binding LCO. This is followed by tissue processing with CRYSTAL 
and HITS. Optically cleared brains are scanned with a SPIM, followed by data analysis. 
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regions and beyond, for each hemisphere. I will include some examples of these datasets but for the 
sake of readability I deposited most of the plots under the link: 
 https://drive.google.com/open?id=1seb2aG1HBU4H-xtINSTr_HOgpv5Pg-iK. The repository is 
organized according to treatment groups. For each treatment a subfolder covers plaque loads, sizes 
and maturity ratios respectively. I generated plots visualizing the fold-change between treatment and 
control of a given read out, further the absolute values of a given readout for control (black box plots) 
and treated (red box plots). For each readout the first 150 brain regions are plotted and are ranked 
according to decreasing statistical significance. Due the limiting size of standard document formats (A4 
page), the 150 regions are plotted in three separate plots covering 50 brain regions each. The three 
plots are identified by the last character of the file name (either blank, 2 or 3). The repository includes 
the respective spreadsheets with the data used for generating the graphs.  
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Effects of anti-amyloid-β therapies 
 
Throughout this work a main guide along which data is organized is the p-value of a given therapeutic 
effect. I interpret this in the sense of effect-robustness. This does not necessarily coincide with the 
strength of an effect but is likely to reflect it in most cases. By effect-robustness I hope to grasp where 
a given therapy shows high reproducibility of an effect. A pitfall of this approach is that there might be 
cases where the p-value is above the significance threshold (p>0.05), since some brain regions may 
have high intrinsic variability. Such variability may have biological or experimental reasons; however, 
it may mask regions otherwise strongly reacting to some therapy. Essentially, this shortcoming is 
intrinsic to this being an endpoint study. 
In the young treatment group, BACE1 inhibition resulted in the most significant (starting from 
p=0.000027) reduction of plaque burden in isocortical areas, with a similar distribution in both 
hemispheres. This was followed by areas of the hippocampal formation and the cortical subplate, 
intermingled with the pons – interestingly. Somewhat less significant effect was seen in the caudo-
putamen and the thalamus. Most regions not reaching the threshold of significance showed reduced 
plaque counts, nevertheless. In general, the regions showing significant (p<0.05) plaque-burden 
reduction showed a postero-basal distribution (Fig. 39 A and B). AβP sizes were also reduced, which 
was less widespread than the reduction in the number of plaques. The most significant plaque size 
reduction, about 2-fold, was seen in sensory isocortical areas (p=0.000724), followed by regions of the 
hippocampus - again intermingled with the pons. In general, plaque-size reduction also showed a 
symmetric postero-basal distribution (Fig. 40). Plaque maturity, expressed as the ratio of emission 
intensities of qFTAA and hFTAA at 498-520 nm and 565-605 nm[62], showed less widespread changes. 
For instance, maturity decreased in more centrally located brain regions like midbrain raphe nuclei or 
thalamic regions. However, plaque maturity increased in a patchy pattern in more superficially located 
isocortical areas (Fig. 41). In contrast to plaque counts and size, relative plaque-core emissions 
(maturity) did not show an obvious postero-basal distribution but rather a contrasting central-
reduction versus a superficial-increase. 
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Figure 39. Plaque-burden reduction by BACE1-inhibition in 5-month-old mice. Map of p<0.05 
plaque burden reduction (a). Fold-change reduction of plaque burden of the first 50 brain regions 





Figure 40. Plaque size reduction by BACE1-inhibition in 5-month-old mice. Map of p<0.05 plaque 
burden reduction (a). Fold-change reduction of plaque size of the first 50 brain regions with 





Figure 41. Plaque maturity change by BACE1-inhibition in 5-month-old mice. Map of p<0.05 plaque 
maturity change (a). Fold-change reduction of plaque size of the first 50 brain regions with 
increasing p-values (0.000164<p<0.1167) in the left hemisphere (b). Green – decrease, blue – 
increase. (For further data see repository.) 
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In the old treatment group, BACE1 inhibition resulted in a up to two-fold reduction of plaque burden 
with the most robust effects in the amygdala (p = 0.000428) and basal ganglia in general, followed by 
isocortical and hippocampal areas (Fig. 42). Intriguingly, AβP sizes showed no relevant reduction but 
the contrary, plaque sizes increased in a few isocortical areas (p = 0.00489) (Fig. 43). AβP maturity 
generally decreased, mostly in isocortical areas (p = 0.00034), followed by some basal ganglia and the 
hippocampus (Fig. 44). Comparing the young and the old BACE1-inhibitor treated group it turned out 
that NB360 is more potent at reducing plaque-counts in the young group. Looking at effect-
distributions, in old animals the effects in the brain stem are much weaker than in young mice for 
example. Surprisingly, the effect on plaque size is profoundly different with a size-reduction in 5-
month-old and increase in 14-month-old mice. Plaque maturity in young mice shows an interesting 
pattern of isocortical size-increase paralleled with a decrease in deeper brain regions. In aged mice 






Figure 42. Plaque-burden reduction by BACE1-inhibition in 14-month-old mice. Map of p<0.05 
plaque burden reduction (a). Fold-change reduction of plaque burden of the first 50 brain regions 





Figure 43. Plaque size reduction by BACE1-inhibition in 14-month-old mice. Map of p<0.05 plaque 
burden reduction (a). Fold-change reduction of plaque size of the first 50 brain regions with 





Figure 44. Plaque maturity change by BACE1-inhibition in 14-month-old mice. Map of p<0.05 
plaque maturity change (a). Fold-change reduction of plaque size of the first 50 brain regions with 
increasing p-values (0.00034<p<0.1071) in the left hemisphere (b). Green – decrease, blue – 
increase. (For further data see repository.) 
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In the young treatment group, the antibody treatment resulted in a patchy pattern of significant 
reduction of plaque burden (starting from p=0.00223), involving isocortical areas, the hippocampus 
and subcortical regions (amygdala) (Fig. 45). Among the patches of significant treatment effect, well 
circumscribed reduction occurred in the inferior colliculus and the brainstem. Comparing individual 
regions between the hemispheres, the list of significantly affected regions differ. However, while 
looking at the effect-distribution maps the patches suggest a more symmetric distribution. A reason 
for this could be that the treatment effects do not respect neuroanatomically defined regions and 
involve region-borders, which causes variations when looking at regions strictly. AβP size alterations 
upon antibody treatment intriguingly showed an AβP size increase in the cortex (p=0.000247) and 
subcortical regions, while AβP sizes decreased in the brainstem (Fig. 46). The plaque decrease in the 
brainstem was only apparent when looking at statistics at the voxel level, suggesting meta-regional 
treatment effects. Plaque maturity, expressed as the ratio of emission intensity of qFTAA and hFTAA, 
showed distinct changes in the brain. Interestingly, AβP maturity showed a consequent decrease in 





Figure 45. Plaque-burden change induced by β1 antibody treatment in 5-month-old mice. Map of 
p<0.05 plaque burden change (a). Fold-change reduction of plaque burden of the first 50 brain 





Figure 46. Plaque-size change induced by β1 antibody treatment in 5-month-old mice. Map of 
p<0.05 plaque size change (a). Fold-change reduction of plaque size of the first 50 brain regions 





Figure 47. Plaque-maturity change induced by β1 antibody treatment in 5-month-old mice. Map of 
p<0.05 plaque maturity change (a). Fold-change in in plaque maturity of the first 50 brain regions 




In the old treatment group, antibody treatment showed a very limited effect on plaque burden, plaque 
size and maturity (Fig. 48-50). Patchy areas of increase and reduction were seen for all readouts. In 
general, both the controls and the treated samples showed higher variability compared to other 
groups, which is apparent when comparing raw readouts to LIN5044 treatment for example (Fig. 51). 
Although raw readouts for plaque counts and size were in a similar range as in the other groups, there 
was an apparent increase in variability in the antibody treated group. Among the explanations for this 
could be some kind of biological variability specific to the treatment. for which I cannot name a reason 
with confidence. One could speculate about differentially manifesting immunoreactions in individual 
animals induced by the antibodies injected (both β1 and control IgG) for example. A seemingly more 
likely explanation would be some experimentally induced variability, for instance by non-
homogeneous tissue clearing within and across samples. However, as tissue transparency is decreasing 
with depth, this would most likely manifest in some discrepancy between the results (both plaque 
burden and its variability) of superficial and deep brain regions. There is no obvious indication of this; 
we observe increased variability in cortical regions as we do in deeper structures.  We see a somewhat 
lower plaque burden and increase in variability in non-specific IgG treated mice compared to PBS 
treated mice (control for the LIN5044 treatment) in general. When comparing the young and the old 
antibody treated group it turned out that treatment effects are in general stronger in the young 
treatment group. The effects on plaque counts are the weakest among the three readouts, while 
effects on plaque size and maturity are dominating the observed effects. Also, the latter two are only 
relevant in the 5-month-old mice, where the effects on plaque size are predominantly distributed in 






Figure 48. Plaque-burden change induced by β1 antibody treatment in 14-month-old mice. Map of 
p<0.05 plaque burden change (a). Fold-change reduction of plaque burden of the first 50 brain 





Figure 49. Plaque size change induced by β1 antibody treatment in 14-month-old mice. Map of 
p<0.05 plaque size change (a). Fold-change in plaque size alterations of the first 50 brain regions 





Figure 50. Plaque-maturity change induced by β1 antibody treatment in 14-month-old mice. Map 
of p<0.05 plaque maturity change (a). Fold-change of plaque maturity alterations of the first 50 
brain regions with increasing p-values (0.005108<p<0.324) in the left hemisphere (b). (For further 





In the young treatment group, LIN5044 treatment resulted in a reduction of plaque burden more in 
subcortical regions, like the amygdala and the thalamus. Also, olfactory areas were significantly 
plaque-count reduced (p=0.0005553). The two hemispheres showed some lateralization, where the 
right hemisphere showed some more patches of significantly affected areas in the cortex (Fig. 52). 
Considering the assumption of the results should be symmetric in the brain, this raises the question of 
some experimentally introduced variability or bias. However, when looking AβP sizes there is no 
obvious asymmetry which would correspond to that seen in plaque density, while both are based on 
the same segmentation data (Fig. 53). In fact, plaque size per se is a readout more sensitive to artefacts. 
AβP sizes showed a widespread and significant reduction in isocortical (p=0.000969), hippocampal and 
subcortical areas. This was similar across the two hemispheres. In general, the distribution of AβP size 
Figure 51. Plaque burden in 14-month-old control mice in the LIN5044 (black) and β1 antibody (red) 
treatment cohorts.  
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reduction seemed to be emphasized more antero-apical. Plaque maturity showed a widespread 
isocortical increase (p=4.0539*10-6), followed by some subcortical regions like the striatum. Small 
patches in deep brain regions close to the midline and in the olfactory bulb showed plaque-maturity 





Figure 52. Plaque-burden reduction after LIN5044 treatment in 5-month-old mice. Map of p<0.05 
plaque burden reduction (a). Fold-change reduction of plaque burden of the first 50 brain regions 





Figure 53. Plaque-size reduction after LIN5044 treatment in 5-month-old mice. Map of p<0.05 
plaque size reduction (a). Fold-change reduction of plaque size of the first 50 brain regions with 





Figure 54. Plaque maturity change after LIN5044 treatment in 5-month-old mice. Map of p<0.05 
plaque maturity change (a). Fold-change reduction of plaque maturity of the first 50 brain regions 
with increasing p-values (4.0539*10-6<p<0.04447) in the left hemisphere (b). Green – decrease, 
blue – increase. (For further data see repository.) 
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In the old treatment group, LIN5044 treatment resulted in the most significant reduction (p = 1.43*10-
6) of plaque burden in the striatum and basal ganglia diffusely (partially more than 2-fold reduction), 
followed by hippocampal areas intermingled with hypothalamic spots and few isocortical regions, in 
decreasing order respectively (Fig.55). The distributions across hemispheres was similar. Most regions 
not reaching the threshold of significance showed reduced plaque counts, nevertheless. Interestingly, 
two regions, the superior colliculus and the posterior visual area, showed non-significant but increased 
plaque burden in both hemispheres. In general, the regions showing significant (p<0.05) plaque-
burden reduction showed an antero-apical distribution (Fig. 55A). AβP sizes showed a widespread and 
vast reduction upon LIN5044 treatment (Fig. 56). The reduction reached levels above 2-fold in some 
cases (anterior amygdalar area, p = 0.00857), however the most robust reduction was displayed in the 
hypothalamus, followed by other subcortical regions like the pallidum and amygdala. Gustatory and 
single isocortical areas followed intermingled with further subcortical regions like the striatum or 
thalamus. In general, plaque-size reduction showed an emphasis on deep-brain regions diffusely, 
although the effect was very widespread.  Plaque maturity showed a distinct pattern of highly 
significant increase (peaking at p=1.12*10-5) in subcortical areas, like the amygdala and other basal 
ganglia and the hypothalamus (Fig. 57). Also, the hippocampus showed strong maturity increase. In 
general, the distribution was similar to how plaque-sizes were affected by LIN5044 treatment. In few 
superficial isocortical areas and the cerebellum a decrease in plaque maturity was seen, for example  
in the piriform area (p = 0.02633). When comparing the young and the old LIN5044 treated group it 
suggests that LIN5044 treatment is more potent in later stages of cerebral amyloidosis. The effect in 
younger mice is stronger on plaque size than plaque counts, which seems to be true in older mice too. 
Plaque maturity is largely increasing by LIN5044 treatment and the effects on maturity largely overlap 
with effects on plaque-size. In general, the treatment effect is pronounced in areas of the brain closer 
to the convexity and to frontal aspects (antero-apical). This distribution is very clear in older mice, but 





Figure 55. Plaque-burden reduction after LIN5044 treatment in 14-month-old mice. Map of p<0.05 
plaque burden reduction (a). Fold-change reduction of plaque burden of the first 50 brain regions 




Figure 56. Plaque-size reduction after LIN5044 treatment in 14-month-old mice. Map of p<0.05 
plaque size reduction (a). Fold-change reduction of plaque size of the first 50 brain regions with 





Figure 57. Plaque maturity change after LIN5044 treatment in 14-month-old mice. Map of p<0.05 
plaque maturity change (a). Fold-change reduction of plaque maturity of the first 50 brain regions 
with increasing p-values (1.12*10-5<p<0.00494) in the left hemisphere (b). Green – decrease, blue 
– increase. (For further data see repository.) 
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Anti-amyloid-β therapies show distinct regional patterns of effect in the whole brain 
 
A fundamental question of this work is whether a basic assumption governing the preclinical 
development of CNS drugs stands. Namely, that by analyzing few thin histological slices from a mouse 
brain one can generalize the effect of a compound to the whole brain. Here, by comparing the 
therapeutic effect-distribution of different compounds, I intended to provide a benchmark towards 
answering this question. We compared the effects of the NB360 BACE1 enzyme inhibitor, the β1- 
antibody, and the LCP LIN5044 on cerebral amyloidosis, by looking at AβP densities, sizes and 
maturation in the whole brain. Statistical comparison between treatment and control groups was done 
on the voxel level. By this I mean that each brain was registered to a standard brain-atlas phantom by 
non-linear transformations, which was followed by the comparison of corresponding voxels between 
the registered brains. These comparisons resulted in maps of significantly affected voxels (SAV). By 
comparing SAV maps between different treatment groups I defined a metric termed significantly 
affected voxel mismatch for different treatments (SAVm). SAVm essentially expresses how different a 
treatment is from the other in terms of the spatial distribution of the treatment effect. SAVm can be 
defined for any two treatments by looking at the proportion of the total volume affected by either of 
the two treatments, and that of overlapping and mismatching volumes. SAVm is more meaningful 
when it is being looked at together with the global brain-wide effect (gSAV) of a respective drug (if a 
drug has very limited effect, looking at distributions becomes less meaningful). gSAV is essentially a 
metric describing how widespread the effect of a drug in the brain is, one may refer to it as “effect 
width”. For example, a hypothetical compound significantly affecting every voxel of the brain (Voxels) 
would have a gSAV = 1, while 50% affected voxels give gSAV = 0.5. 
SAVm for treatments “A” and “B”, are as follows, where the units are voxels and each set represents 
the number of voxels contained: 
1.     𝑆𝑆𝑆𝑆𝑆𝑆𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 = 𝑆𝑆𝑆𝑆𝑆𝑆𝐴𝐴 ∪ 𝑆𝑆𝑆𝑆𝑆𝑆𝐵𝐵 
2.      𝑆𝑆 = 𝑆𝑆𝑆𝑆𝑆𝑆𝐴𝐴\𝑆𝑆𝑆𝑆𝑆𝑆𝐵𝐵, and 
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      𝐵𝐵 = 𝑆𝑆𝑆𝑆𝑆𝑆𝐵𝐵\𝑆𝑆𝑆𝑆𝑆𝑆𝐴𝐴 
3.     𝑆𝑆&𝐵𝐵 = 𝑆𝑆𝑆𝑆𝑆𝑆𝐴𝐴 ∩ 𝑆𝑆𝑆𝑆𝑆𝑆𝐵𝐵 
arithmetically: 
4.     𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝐴𝐴 = 𝑆𝑆/𝑆𝑆𝑆𝑆𝑆𝑆𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 , and 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝐵𝐵 = 𝐵𝐵/𝑆𝑆𝑆𝑆𝑆𝑆𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 
Where 𝑆𝑆𝑆𝑆𝑆𝑆𝐴𝐴 and 𝑆𝑆𝑆𝑆𝑆𝑆𝐵𝐵 are the set of voxels significantly affected by treatment A or B respectively, A 
and B are voxels only affected by A or B treatments respectively, while A&B are voxels affected both 
by A and B treatments. 





To which for more convenient interpretation corresponding percentages can be assigned: 
 
Naturally, these metrics can analogously be applied to specific brain regions. For instance, in some 
study of a drug with a specific target one could quantify how effective a drug is in a certain nucleus 
and consider all the other regions with significant effect as potential loci of side effects.  
gSAV is: 
5.      𝑔𝑔𝑆𝑆𝑆𝑆𝑆𝑆𝐴𝐴 = 𝑆𝑆𝑆𝑆𝑆𝑆𝐴𝐴/Voxels, 
Where “Voxels” is the number of voxels contained in the brain, essentially a constant (in our brain 
model 29026256 voxels).  
At the same time the effect of a drug is not only described by the spatial distribution of the effect, but 
by the degree of alteration, e.g. AβP density reduction, it elicits locally. A convenient way of grasping 
this is simply by the “p” probability value of significance. Hence, the p-value maps presented previously 
can be utilized for this. Accordingly, to give a more realistic picture about how drug effects and their 
respective effect-strength are distributed I also defined weighed SAV (wSAV) by summing the 
reciprocal of the respective probability values. For treatment “A”, wSAV is: 
6.      𝑤𝑤𝑆𝑆𝑆𝑆𝑆𝑆𝐴𝐴 = �  𝑥𝑥 1𝑝𝑝𝑥𝑥𝑥𝑥∈𝐴𝐴  
 
Following which, essentially all the metrics defined in points 2-5 can defined also as a function of wSAV. 
wgSAV (weighed global SAV) can be normalized by SAV which provides a handle on the steepness or 
strength of the therapeutic effect, which becomes more meaningful when comparing therapies. For 
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example, a therapy can have widespread rather weak effects, while another one is more localized but 




Along these lines of thought we compared the effects on AβP density of BACE1 inhibition and antibody 
treatment in 14-month-old mice. NB360 showed a profoundly stronger effect in reducing plaque 
counts (gSAV = 0.22) than the β1 antibody (gSAV <0.01) (Fig. 58). Essentially the antibody treatment 
showed mostly a slight -almost negligible-, patchy increase in plaque densities both in the isocortex 
and in subcortical areas. The effect of NB360 had a strong isocortical emphasis together with 
subcortical, e.g. amygdalar effects. Accordingly, the two treatments showed highly differing SAVm 
(SAVmNB360 = 97%, SAVmβ1 = 2%) brain-affection. wSAV values normalized by the SAV count, as an 
expression of average effect-robustness, were in a similar range for the two treatments (NB360 = ~172, 
β1 antibody = ~178). 
 
When comparing BACE1 inhibition with antibody treatment in the 5-month-old group, we clearly saw 
that the treatments result in highly separated effect-distributions (Fig. 59). One obvious reason for this 
Figure 58. Plaque-burden reduction after NB360 and β1-antibody treatment in 14-month-old mice. 
Virtual coronal slices with corresponding p-value maps of p<0.05 plaque burden change (heatmap: 
magenta – reduction, cyan - increase) (a). Significantly affected voxel overlap (yellow) and 
mismatch of β1-antibody (blue) and NB360 (cyan) treatment (b, left). Significantly affected voxels 
in relation to the total brain volume (yellow) after NB360 treatment (blue)(b, middle). Significantly 




is that the antibody treatment had a far more restricted effect (gSAVβ1 = 0.09, gSAVNB360 = 0.36). Also 
for this reason, it is not evident how to describe effect distribution in the antibody treated group. 
However, the NB360 treatment showed a postero – basal effect distribution. The two treatment 
modalities overlapped in 12% of the total of SAV, which is half of the voxels affected by the antibody 
(SAVmβ1 = 12%). SAVmNB360 equaled 77%. This suggests, that these two drugs tend to overlap in their 
effect locales.  Looking at wSAV values normalized by the respective SAV counts, β1- treatment showed 
more localized but salient effects compared to NB360 treatment (β1 = ~151, NB360 = ~89). 
 
Figure 59. Plaque-burden reduction after NB360 and β1-antibody treatment in 5-month-old mice. 
Virtual coronal slices with corresponding p-value maps of p<0.05 plaque burden change (heatmap: 
magenta – reduction, cyan - increase) (a). Significantly affected voxel overlap (yellow) and 
mismatch of β1-antibody (blue) and NB360 (cyan) treatment (b, left). Significantly affected voxels 
in relation to the total brain volume (yellow) after NB360 treatment (blue)(b, middle). Significantly 




Comparing BACE1 inhibition with LIN5044 treatment in the old (14-months) group clearly showed an 
approximately 30% overlap of their respective plaque-count reducing effect distributions (SAVmLIN5044 
= 44%, SAVmNB360 = 32%, SAVmNB360&LIN5044 =24%) (Fig. 60). Both treatments affected around one quarter 
of the voxels in the brain (gSAVNB360 = 0.22, gSAVLIN5044 = 0.27) significantly. SAV normalized wSAV values 
showed that the NB360 treatment is albeit somewhat less broad, but more robust (NB360 = ~173, 
LIN5044 = ~131). 
 
 
Looking at plaque sizes when comparing 14-month-old NB360 and LIN5044 treated mice was 
interesting, as the effect of NB360 on plaque size was highly different at 5- and 14-months. In general, 
for simplicity I infer the amyloidosis-burden from plaque-counts, however, in this case this was not 
necessarily appropriate (the total amyloid volume would be the most comprehensive approach). In 
Figure 60. Plaque-burden reduction after LIN5044 and NB360 treatment in 14-month-old mice. 
Virtual coronal slices with corresponding p-value maps of p<0.05 plaque burden change (heatmap: 
magenta – reduction, cyan - increase) (a). Significantly affected voxel overlap (yellow) and 
mismatch of LIN5044 (blue) and NB360 (cyan) treatment (b, left). Significantly affected voxels in 
relation to the total brain volume (yellow) after NB360 treatment (blue)(b, middle). Significantly 




this comparison of 14-month-old mice, SAVm for plaque-size decrease was dominated by the LIN5044 
treatment (SAVmLIN5044 = 98%, SAVmNB360 = 1%). Accordingly, looking at brain-wide voxel-involvement 
in treatment-effect showed gSAVNB360 = 0.01, while gSAVLIN5044 = 0.57. Plaque size increase was 
essentially a non-existent effect upon LIN5044 treatment and SAVm was dominated by the NB360-
effect (SAVmNB360 = 0.98) at gSAVNB360 = 0.04 and gSAVLIN5044 = ~0.0018 (Fig. 61). 
  
 
Figure 61. Plaque-size decrease and increase after LIN5044 and NB360 treatment in 14-month-old 
mice. Virtual coronal slices with corresponding p-value maps of p<0.05 plaque burden change 
(heatmap: magenta – reduction, cyan - increase) (a). Significantly affected voxel overlap (yellow) 
and mismatch of LIN5044 (blue) and NB360 (cyan) treatment (b, left). Significantly affected voxels 
in relation to the total brain volume (yellow) after NB360 treatment (blue)(b, middle). Significantly 




When looking at 5-month-old mice, in contrast to aged mice the LIN5044 treatment showed a far 
weaker effect compared to NB360 treatment (Fig. 62). SAVmNB360 was 80% while SAVmLIN5044 was 13%, 
the treatments overlapped in 7% of the voxels. gSAVNB360 equaled 0.36, while gSAVLIN5044 resulted in 
0.08. SAV normalized wSAV values however, showed more robust effects for the LIN5044 affected 
areas than for the NB360 affected regions (LIN5044 = ~174, NB360 = ~89). Unlike in 14-month-old 
mice, BACE1 inhibition in 5-month-old mice resulted in similar distributions of plaque-size- and plaque 
count reduction (Fig. 60-61). At the same time, while LIN5044 had a weak effect on plaque-counts in 
5-month-old mice, it maintained its widespread effect on reducing plaque sizes (Fig. 62-63). 
Intriguingly, the difference in effect-distribution when looking at plaque sizes showed almost an 
inverse distribution between LIN5044 and NB360 (Fig. 63). Effect-widths were almost identical 
(gSAVNB360 = 0.30, while gSAVLIN5044 = 0.32), while only 23% of affected voxels overlapped (SAVmLIN5044 





Figure 62. Plaque-burden reduction after LIN5044 and NB360 treatment in 5-month-old mice. 
Virtual coronal slices with corresponding p-value maps of p<0.05 plaque burden change (heatmap: 
magenta – reduction, cyan - increase) (a). Significantly affected voxel overlap (yellow) and 
mismatch of LIN5044 (blue) and NB360 (cyan) treatment (b, left). Significantly affected voxels in 
relation to the total brain volume (yellow) after NB360 treatment (blue)(b, middle). Significantly 






Comparing LIN5044 with antibody treatment in the old group showed a clear separation of the two 
treatments in their effect on AβP burden. Obviously, since the antibody treatment had a very limited 
therapeutic effect while LIN5044 had a robust and widespread effect, major differences emerged. 
While the antibody treatment effects showed a patchy distribution more in the deep regions, the 
LIN5044 treatment showed a confluent antero-apical distribution (Fig. 64). Spatially, the treatment-
effects overlapped in less than 1% of the voxels, while 98% was assigned to LIN5044 treatment and 2% 
to the antibody treatment only. From the total brain volume, LIN5044 had an effect on 27% of all brain-
voxels, while the antibody only affected less than 1%. Looking and p-value-weighed effect on plaque 
burden (wSAV) LIN5044 had a 29.1-fold stronger effect. SAV normalized wSAV values were in a similar 
range (LIN5044=~131, β1 = 178). 
Figure 63. Plaque-size decrease after LIN5044 and NB360 treatment in 5-month-old mice. Virtual 
coronal slices with corresponding p-value maps of p<0.05 plaque burden change (heatmap: 
magenta – reduction, cyan - increase) (a). Significantly affected voxel overlap (yellow) and 
mismatch of LIN5044 (blue) and NB360 (cyan) treatment (b, left). Significantly affected voxels in 
relation to the total brain volume (yellow) after NB360 treatment (blue)(b, middle). Significantly 






In 5-month-old mice LIN5044 treatment compared to antibody treatment resulted in very similar 
involvement of brain-voxels (mSAVLIN5044 = 44%, mSAVβ1 = 50%, with 5% overlap) and gSAVβ1 = 0.09, 
while gSAVLIN5044 = 0.08. Also normalized wSAV values were similar (β1 = 151, LIN5044 = 164) (Fig. 65). 
Upon antibody treatment plaque sizes increased in contrast to LIN5044, where plaque sizes were 
decreasing after treatment (Fig 46 and 53). 
Figure 64. Plaque-burden reduction after LIN5044 and β1-antibody treatment in 14-month-old 
mice. Virtual coronal slices with corresponding p-value maps of p<0.05 plaque burden change 
(heatmap: magenta – reduction, cyan - increase) (a). Significantly affected voxel overlap (yellow) 
and mismatch of LIN5044 (blue) and β1-antibody (cyan) treatment (b, left). Significantly affected 
voxels in relation to the total brain volume (yellow) after β1-antibody treatment (blue)(b, middle). 





Figure 65. Plaque-burden reduction after LIN5044 and β1-antibody treatment in 5-month-old mice. 
Virtual coronal slices with corresponding p-value maps of p<0.05 plaque burden change (heatmap: 
magenta – reduction, cyan - increase) (a). Significantly affected voxel overlap (yellow) and 
mismatch of LIN5044 (blue) and β1-antibody (cyan) treatment (b, left). Significantly affected voxels 
in relation to the total brain volume (yellow) after β1-antibody treatment (blue)(b, middle). 




In summary our results show that: 
1. effect width (gSAV) in 5-month-old mice in increasing order 
LIN5044 (0.08) < β1-antibody (0.09) < NB360 (0.36), 
while in 14-month-old mice,  
β1-antibody (<0.01) < NB360 (0.22) < LIN5044 (0.27). 
2. LIN5044 is potently reducing plaque sizes in both age groups. 
3. NB360 decreases plaque size in young mice and increases plaque size in old mice. 
3. β1-antibody treatment has no strong effect, it is however more effective in young mice. Here it 
decreases plaque counts and increases plaque size. 
4. LIN5044 shows a particular antero-apical effect-distribution in 14-month-old mice (plaque density 
and size) and in 5-month-old mice (plaque size), while NB360 shows a strongly contrasting postero-
basal effect-distribution in 5-month-old mice. 
5. Most treatments have mostly non-overlapping effect-distributions. 
6. Decrease in plaque size is accompanied by increase in maturity ratio, while increase in plaque size is 





Effects of AD-therapeutics in the whole brain 
 
The main point of my work aimed at understanding drug-effect distributions in whole-mount AD 
brains. We hypothesized that 2D histological sectioning is limited in its capability in providing a 
comprehensive picture of drug effects. This is even more true for an organ as heterogeneous as the 
brain. By developing a pipeline for rapid tissue clarification and staining combined with light-sheet 
microscopy, we could test how drug effects are distributed in the brain of transgenic mice modelling 
Alzheimer’s disease. 
Assessing the effect of anti-AD drugs is generally done by the biochemical measurement of crude β-
amyloid loads or stereology, for example on 15-20 slices per brain [59, 137, 138]. Stereological 
quantification of amyloid loads uses for example percentage of antibody stained area in relation to the 
total surface analyzed, or by counting plaques. Not for testing therapeutic compounds but as a proof 
of principle it was shown, that with tissue clearing approaches amyloid plaque loads in the whole brain 
can be quantified[139]. However, in this rather methodological work only plaque-counts were being 
looked at. In another study, AβP quantification including plaque-sizes was attempted in cleared whole-
mount mouse brains, however it is not clear what degree of transparency was achieved and whether 
the analysis was not limited to rather superficial brain regions only[140]. We hypothesized, that the 
there is potentially more information in tissues of animals subjected to drug tests, than what one can 
extract with standard biochemical and histological methods. One reason for this resides with the high-
degree of heterogeneity within the brain, which makes generalizations from few tissue slices difficult. 
We assumed, that there is much to be learned about different drugs and amyloidosis by looking at 
brain-wide effect-distributions. 
We tested three compounds, an amyloid-β antibody (β1)[60], a BACE1 inhibitor (NB360)[58] and a 
polythiophene compound (LIN5044)[61] in the APP/PS1 mouse model[56]. Mice were treated for three 
months, starting at ages of either 2 months (young) or 11 months (old). Mice received drug-loads 
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similar to those published before. When designing treatment cohorts, I aimed to contain 3 treated 
females and 3 treated males, with corresponding 3 females and 3 males receiving vehicle. We lost few 
animals and samples due to spontaneous death and due to single cases of genotyping error. Few 
samples got damaged during tissue processing leading to the final number of samples analyzed (Table 
1). We looked at plaque counts, plaque sizes and plaque maturity. Plaque maturity we established 
based on the work of Nystrom and colleagues[62], where it was shown that by using the amyloid 
staining compounds qFTAA and hFTAA, the compactness of AβPs can be assessed. This compactness, 
or maturity, is inferred from the ratio of qFTAA and hFTAA being bound to the plaque. As qFTAA tends 
to bind more to compact amyloid in the core of plaques, the binding and emission of qFTAA increases 
in the core of the plaques with time.  










control 5 4 4 5 4 6 
treated 3 6 5 3 4 6 
Table 1. Number of mice in treatment cohorts. 
We found that the β1 antibody treatments showed a limited therapeutic effect on amyloid deposits. 
Essentially, plaque-count reduction occurred in the young cohort only, accompanied by plaque-size 
increase and a concomitant plaque-maturity decrease.  The distribution of the therapeutic effect did 
not follow any defined neuroanatomical pattern. There was a patchy cortical distribution with some 
treatment effects in basal aspects of the striatum and amygdala. In general, the limited effect of the 
β1 antibody on morphologically measured amyloid load is in line with the literature. It was shown, that 
β1-antibody application has no obvious plaque-reducing effect in younger and older mice[141]. At the 
same time, it was shown that it reduces dendritic pathology at younger age (5 months) and increases 
the amount of soluble antibody-bound fibrils and protofibrils. Furthermore, it was described that there 
is a slight increase in plaque associated non-modified amyloid-β. These findings could well explain what 
we observed. Namely, that in the old age group we barely see an effect, but in the young age group 
there is an increase in plaque size. The increase in plaque size potentially recapitulates the increase of 
plaque-associated non-modified amyloid-β load. An explanation could be that antibody-bound 
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amyloid-β species (suggested to be fibrils and protofibrils) are prevented from being incorporated into 
the cores of plaques, and rather aggregate on the less compact and less structured outer aspects of 
plaques. Thereby the size of plaques increases paralleled by a decrease in plaque-core density as 
shown by the reduced qFTAA/hFTAA ratios. The experiments in the discussed paper were done in 
APP23 mice which have slower kinetics of AβP accumulation[141]. Therefore, a side-to-side 
comparison to our results is not possible. It is not clear how to explain what was described in another 
paper, where also APP23 mice were treated with the same antibody, but a reduction in amyloid-β 
pathology (mostly that of the diffuse type) and of Aβ-42 load was measured[59]. In this paper however, 
very old mice were used (21 months) which may present a different pathophysiological setting. In a 
longitudinal 2-photon microscopy study, also other antibodies were described to have negligible 
effects on amyloid plaque loads[142]. Although I just did elaborate on the limited effect of the β1-
antibody treatment on AβP counts, in fact we did see some patchy reduction of AβP density in young 
mice. This allows me to speculate, that the study where no AβP-reducing effect was seen may have 
used regions for histology which were not therapy-affected, while the other study may have included 
regions which did react to the treatment. This highlights the importance of studying therapy effects in 
a holistic manner, especially before concluding on morphologically defined drug-effects. Potentially, 
opposing conclusions were drawn in well conducted studies while both observations were true 
essentially. 
Interfering with the production of amyloid-β as it is attempted by the inhibition of BACE1, is another 
prominent therapeutic approach in AD. Our experiments showed that by treating mice with NB360, 
the strongest reduction in AβP load can be achieved in young mice. However, in aged animals the effect 
of NB360 is less widespread (SAVg of 0.36 in young and 0.22 in aged mice). Interestingly, there seems 
to be a particular distribution on therapeutic effect, especially in young animals. Regions mostly 
targeted by NB360 include postero-basal aspect of the brain. This is paralleled by the intriguing aspect, 
that while in young mice both plaque counts and sizes are reduced, in old mice plaque-sizes increase. 
One could speculate, that there is a dynamic balance of different mechanisms governing AβP 
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pathogenesis.  Primary nucleation in the early stages of AβP biogenesis, which is a process depending 
on amyloid-β concentrations[143], is paralleled by secondary nucleation. Secondary nucleation is more 
a qualitative phenomenon depending on the presence of certain amyloid-β species, most likely 
oligomeric ones, serving as templates for nucleation[127, 144-147]. In young animals, where de novo 
plaque generation kinetics are cubic, plaque generation is likely to be governed by the concentrations 
of amyloid-β monomers in the sense of primary nucleation[148]. Hence, BACE1 inhibition has a robust 
effect on de novo AβP generation[149]. Hypothetically, at this young age there is no abundance of 
mature amyloid-β species for templated amyloid accumulation around plaques, which could also 
explain the early lag phase of plaque growth in young mice[148]. Hence, upon the strong amyloid-β 
concentration reducing effect of NB360, the remaining monomers rather contribute to a slower de 
novo plaque generation than to aggregation around preexisting plaques. This may explain the strong 
decrease of both AβP counts and sizes. At later stages, when more mature and heterogeneous amyloid 
species are present, primary and secondary nucleation are competing for the amyloid-β monomers 
available. Drastically reducing the concentration of monomers with NB360, may lead to sub-threshold 
monomer concentrations for primary nucleation. In such a situation the remaining monomers are fully 
incorporated into preexisting plaques and lead to such a counter-intuitive size-increase. A possibility 
to consider is that by reaching subthreshold monomer concentrations, much fewer plaques are de 
novo generated in some areas, leading to a statistical overrepresentation of large plaques. At this point 
it is also important to note that as plaques increase in size and mass, even a constant rate of further 
mass increase will lead to more-and-more incremental increase in radius. The decreasing increase of 
plaque radius may reach an extent where the resolving power of the microscope is insufficient. It is 
not clear how this was accounted for in previous studies[148, 149]. Considering plaque-counts at older 
ages where there is an abundance of plaques already, even at a putative constant rate of de novo 
plaque generation the relative increase in plaque counts will decrease. Therefore, the impact of any 
drug affecting plaque-generation will become necessarily less prominent relative to total plaque 
counts.  By applying NB360, the de novo generation of amyloid-β is decreased. At this later stage in old 
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mice however, the effect of amyloid-β monomer decrease has a less prominent effect. First, the 
relative increase in plaque counts is anyway lower due to the high baseline plaque-load. Second, as 
just discussed, primary nucleation-based de novo AβP generation is being competed by templated 
misfolding and aggregation, due to abundant nucleation seeds provided by mature amyloid-β species. 
It is conceivable that while there is weaker therapeutic effect of NB360 on de novo AβP generation in 
aged mice, the yet available amyloid-β monomers are readily recruited by certain forms of plaques 
which thereby increase in size. This recruitment and aggregation of amyloid-β by plaques may lead to 
the incorporation of “freshly” misfolded non-mature monomers. This could explain the decrease in 
plaque-core density based on qFTAA/hFTAA ratios. It is unclear how such a redistribution of amyloid-
β into AβPs, which are essentially amyloid-β reservoirs, affects the balance of different amyloid-β 
species. One could imagine that this is beneficial as potential toxic species are incorporated into 
plaques. The contrary may also be true, that by the facilitation of templated misfolding more toxic 
forms are generated and slowly released from AβPs.  As large plaques may serve as potential reservoirs 
for toxic amyloid species, mitigating or stabilizing these reservoirs may be highly desirable. 
A highly serendipitous result of my work is the therapeutic effect of LIN5044 in APP/PS1 mice. Applying 
this compound had some rationale as it was shown to have beneficial effects in prion infected 
mice[61]. However, as LIN5044 was designed for prion amyloids it was not clear whether it would 
affect amyloid-β too. Also, in some personal communication I was informed that polythiophene 
compounds were tested in cerebral amyloidosis models in the past, but no clear effect was seen. In 
young mice LIN5044 did not show a very widespread effect on plaque density. It reduced plaque counts 
in a patchy distribution. However, it showed a widespread effect on plaque-sizes. Plaque sizes were 
reduced with a somewhat antero-apical emphasis. Plaque size reduction was paralleled by an increase 
in plaque-core compactness or maturity. In aged mice the effect of LIN5044 surpassed every 
expectation, as it was the most potent compound from the three tested here. It showed the most 
widespread effect in reducing plaque-counts, paralleled by a very broadly distributed and profound 
reduction of plaque sizes. Plaque count reduction showed a distribution in antero-apical aspects of the 
143 
 
brain, which was more distinct in old mice than in young mice. Plaque-size reduction was paralleled by 
an increase in plaque-core compactness. It was proposed that by administering LIN5044 to prion 
infected mice amyloid fibrils are stabilized, which in turn are less prone to fragmentation and the 
production of new seeds or propagons  for amyloid templating and spreading[61]. This could to some 
extent also explain these results. However, one could also postulate a mechanism where LIN5044 binds 
to a distinct pocket on amyloid fibrils, whereby it interferes with templated misfolding. Arguably, the 
process governing plaque growth is templated misfolding, fibril growth and aggregation. A putative 
interference with templated misfolding or aggregation, could well explain why plaques in LIN5044-
treated mice are prevented from growing. As mentioned before, LIN5044 did not only decrease plaque 
sizes, but also decreased plaque counts. One could speculate that in aged mice de novo plaque 
generation may either be primary nucleation based, and/or governed by secondary nucleation. It is 
likely that there is an abundance of various amyloid-β species in aged mice, most likely some of them 
also prone to seed new plaques. I would argue, that the strong reduction of plaque-counts in aged 
mice could also be explained by LIN5044 interfering with secondary nucleation-based de novo plaque 
generation. Congruently with this hypothesis, in young mice where secondary nucleation is probably 
not the main driver of de novo plaque genesis, the effect of LIN5044 on plaque-counts is the least from 
the tested compounds while plaque-size reduction is nevertheless prominent. By blocking the 
misfolding and incorporation of amyloid-β into plaques, AβPs will contain proportionally less non-
mature amyloid. This could explain the relative increase in plaque compactness or maturity. 
The fact that BACE1 inhibition proves to be more potent at early stages of cerebral amyloidosis, while 
LIN5044 has a profound disease-modifying effect at later stages, suggests that the combination of 
these approaches may lead to more than an additive therapeutic effect.  The combination of anti-
amyloid-β therapies has been proposed before[150], however not such a combination. Here we 
propose to combine an enzyme inhibitor lowering amyloid-β concentrations, with an amyloid stabilizer 
or templating-inhibitor. Countless anti-fibrillation compounds, β-sheet breakers like benzofuranes, 
Congo-red, curcumin or olive-biophenols just to mention few, were shown to be effective in reducing 
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amyloid pathology both in vitro and in vivo[151-155]. However, none of these – without attempting a 
comprehensive review - was advanced into patient care[156]. Therefore, I do not intend to overstate 
the potential LIN5044 may carry. Nevertheless, using such a compound in combination with an 
orthogonal approach, like BACE1 inhibition, may be promising. 
Taken together, our results show that different therapeutic approaches show distinct propensities to 
certain areas of the brain. Further, by looking at multiple morphological descriptors of the disease 
model we unraveled differences between therapies, which are beyond merely quantitative mono-
dimensional differences. The differences between therapies I elaborated on, allowed me to form 
hypotheses about pharmacodynamic properties of the different drugs. These hypotheses need to be 
tested in future works. Importantly, these results could not have been obtained without the use of 3D 
histology of entire mouse brains. Therefore I argue, that with the emergence of tissue clarification 
methods the gold standards of histological phenotypisation need to be revisited in the scientific 
community. A serendipitous result of this study is the potent reduction of amyloid pathology by 
LIN5044, which until disproved, is a potential drug candidate in amyloidogenic proteinopathies. We 
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